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Metastatic disease is the major cause of death in all solid tumor
cancers. Current therapeutic strategies fail to target metastasis as the
genes and mechanisms that regulate this process remain poorly
understood. Metastatic colonization is the final step of the metastatic
cascade whereby cancer cells form a tumor at a distant site. This final step
is the culmination of clonal evolution of cancer populations that results in
a highly aggressive population with enhanced metastatic capacity and
often presents clinically as numerous inoperable tumor nodules that lead
to mortality. Characterization of the mechanisms that govern metastatic
colonization at cellular and molecular levels is necessary for the
prevention and treatment of metastatic disease in patients.
The first half of this thesis presents work towards understanding
mechanisms that mediate colorectal cancer colonization of the liver in
order to guide novel therapeutic strategies. An in vivo large-scale RNAinterference screen was performed to identify genes required for liver
colonization. Liver and red blood cell pyruvate kinase (PKLR) was
identified as a driver of liver metastasis in experimental models. In
patients, PKLR was found to be expressed at higher levels in liver
metastases relative to primary colorectal cancer tumors and also overexpressed in the primary tumors of patients with metastatic disease. PKLR

was found to promote cell survival in the tumor core and enhance
survival during conditions of concurrent high cell density and low oxygen
availability. Molecular studies revealed that PKL negatively regulates
pyruvate kinase M2 (PKM2) enzymatic activity. By inhibiting cellular
pyruvate kinase activity, PKLR allows for the diversion of metabolites
towards glutathione generation—allowing for the maintenance of
glutathione levels. Adequate glutathione levels appears critical for
metastatic colonization as GCLC, the catalytic subunit of glutamatecysteine ligase and the rate-limiting enzyme for glutathione synthesis, was
found to be similarly required for effective metastasis, associated in its
expression with human liver metastatic progression, and could be
therapeutically targeted to reduce metastatic colonization. These findings
highlight the impact of metabolic regulation on cancer cell adaptation
within the metastatic niche.

The robust effects on liver metastatic

colonization observed upon modulating this metabolic pathway suggest
clinical potential for therapeutic targeting of PKLR or cellular glutathione
synthesis in colorectal cancer.
The second half of this thesis presents work towards an
understanding of diversity generation in clonal populations as it benefits
cancer evolution and metastatic colonization. Clonal human breast cancer
subpopulations were isolated to allow for the identification of
subpopulations that exhibit population-level phenotypic diversity. These
high variability clonal subpopulations were found to be more proficient at
metastatic colonization—consistent with a positive role for diversification
capacity in cancer progression. Through single-cell RNA-sequencing, cell-

to-cell transcript expression variability was identified as a defining feature
of

these

subpopulations,

extending

to

protein-level

variability.

Furthermore, spliceosomal machinery was identified as a gene set with
high expression variability, suggesting a means by which variation could
be transmitted to a global level. Engineered variable expression of the
spliceosomal gene SNRNP40 promoted metastatic fitness, and this
metastatic capacity was attributable to cells with low SNRNP40
expression. Clinically, low SNRNP40 expression is associated with
metastatic relapse. These findings reveal that transcriptomic variability
generation may serve as a mechanism by which cancer subpopulations
achieve diversification of gene expression states, which allows for
enhanced fitness under changing environmental pressures encountered
during metastatic progression.

For Ba và Mẹ
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CHAPTER 1: Introduction

1

Metastasis as a major cause of cancer death
Cancer is the second most common cause of death in the United
States, accounting for an estimated 589,430 deaths in 2015 (Siegel et al.,
2015). It is estimated that 90% of these deaths is a result of metastasis,
when cancer cells leave the site of the primary tumor and develop a tumor
in a distant organ (Mehlen and Puisieux, 2006; Weigelt et al., 2005).
Despite the significant clinical impact, current therapies fail to affect
metastatic outcomes, which is highlighted by the drastically low 5-year
survival rates of metastatic breast and colorectal cancer, two of the most
prevalent and deadly cancers in the US (Figure 1.1)(Siegel et al., 2015).
There currently does not exist any therapy with broad metastasissuppressive activity as the mechanisms that regulate metastasis remain
poorly characterized (Chiang and Massague, 2008).

Figure 1.1: 5-year survival for breast and colorectal cancer
Survival rates as calculated by Siegal et al., 2015 for breast (a) and
colorectal (b) cancers. Local stage is defined as no spread to lymph nodes
or nearby structures. Regional stage is defined as spread to nearby tissues
or lymph nodes. Distant stage is defined as spread to distant lymph nodes
or organs.
2

The metastatic cascade and organ tropism
Metastasis is a complex, multi-step process whereby cancer cell
populations survive and expand through a series of different selective
pressures before a tumor can form in a distant organ (Illustration 1.1).
During early stages of metastasis, cancer must first locally invade through
the basement membrane of the tissue wall, allowing for access to local
lymphatic and hematogenous circulation (Gupta and Massague, 2006;
Valastyan and Weinberg, 2011). Cancer populations must survive in
circulation until arrival at a distant organ, where successful extravasation,
adaptation to microenvironmental pressures, and cancer population
growth must occur to allow for continued cancer progression (Talmadge
and Fidler, 2010). Metastatic colonization is the final step of this process,
which is defined as the capacity of cancer cells that have arrested at a
distant organ to develop into macroscopic metastatic tumor nodules.

3

Illustration 1.1: The metastatic cascade
Cancer populations that develop in the primary site must invade through
the basement membrane, intravasate into circulation, survive in transit
until arresting at a distant organ. Populations must then successfully
extravasate into the distant organ where colonization must occur before a
macroscopic metastasis is formed.

4

Much of the difficulty in broadly impacting metastasis in the clinic
can be attributed to the heterogeneity of metastasis. While primary tumors
from cancers of different types harbor similar oncogenic and tumorsuppressive mutations that enables deregulation of pathways essential to
tumorigenesis (Hanahan and Weinberg, 2000), metastatic cancer varies in
its presentation clinically and in its phenotypic capabilities depending on
the cancer type. Clinicians have long been aware that cancer types differ
in their propensity to colonize distant organs—metastatic breast cancer
most commonly occurs in the lung, liver, bone and brain, whereas
metastatic colorectal cancer most commonly occurs in the liver (Fidler,
2003). This inherent propensity was originally attributed to anatomy as it
was proposed by Virchow in 1858 that cancer cells dislodged from a
primary tumor follow circulation to form emboli in the vasculature of
distant organs (Virchow, 1989). This theory was further advanced by
Ewing in 1928 who proposed that circulatory architecture and mechanical
forces dictated organ specificity (Ewing, 1928). The countering theory of
metastasis was developed by Paget in 1889, who noted from autopsy
records that in addition to the lungs, metastatic breast cancer
preferentially colonized bones, liver and ovaries—organs that do not
immediately follow the breast in the circulatory system (Paget, 1989). This
preferential metastatic colonization led Paget to generate the “seed-andsoil” hypothesis in which he posited that cancer cells disseminate to many
organs, but that macroscopic metastases develop only at the sites
permissive to cancer cell survival and growth. Studies by Fidler nearly a
century later revealed that while cancer cells arrive and can arrest in
5

nearly all organs, metastatic colonization only occurs in select organs,
confirming Paget’s hypothesis and indicating that biological factors at the
metastatic niche can dictate organ specificity (Hart and Fidler, 1980). Fider
and colleagues also demonstrated that subpopulations in a primary tumor
contribute to the metastatic population, indicating that cancer cells possess
inherent biological features that enable metastatic potential (Fidler and
Kripke, 1977). Together, it is now understood that molecular drivers from
both the cancer cells as well as the metastatic niche contribute to the
development of macroscopic metastases.
Organ tropism has been validated at the molecular level where
functional studies have revealed distinct molecular drivers in breast
cancer populations enable proclivities to colonize the bone, brain, lung,
and liver (Bos et al., 2009; Kang et al., 2003; Minn et al., 2005; Tabaries et
al., 2011). Importantly, metastatic cancer cells require distinct phenotypic
abilities to colonize different organs. Breast and melanoma cancer cells
that colonize the lung depend heavily on the ability to migrate through
endothelium, invade through extracellular matrix, and recruit endothelial
cells for continued tumor growth (Pencheva et al., 2012; Png et al., 2012;
Tavazoie et al., 2008). Colorectal cancer appears more dependent on
adequate cancer cell energetic supply to survive in the hypoxic liver
microenvironment during initial colonization of the liver (Loo et al., 2015).
Molecular and cellular characterization of these driver genes and
pathways in various cancer types and organs have allowed for the
potential development of novel strategies to therapeutically target
metastasis (Loo et al., 2015; Pencheva et al., 2014; Pencheva et al., 2012).
6

The heterogeneity between cancer types illustrates how focused
characterization

of

cancer

type-specific

mechanisms

that

govern

metastatic colonization can be translated into clinical therapies.

Clonal evolution during the metastatic cascade
The understanding of the metastatic cascade as a step-wise
progression of a population with increasing aggressiveness is based on the
model of clonal evolution of cancer populations first proposed by Nowell
in 1976 (Nowell, 1976). Based on Darwinian natural selection, this model
proposes that cancer populations progress via mutational events that
provide a fitness advantage through rounds of selective pressures
(Illustration 1.2). This model was delineated in patients most notably by
Vogelstein who observed an association between specific driver mutations
with the aggressiveness of early stage of colorectal cancer (Vogelstein et
al., 1988). More recently, whole-genome sequencing has revealed that
within individual tumors, subclonal expansion of cancer populations
during cancer progression can be attributed to the effect of specific driver
mutations (Ding et al., 2012; Gerlinger et al., 2012; Juric et al., 2015),
consistent with Nowell’s model.

7

Illustration 1.2: Clonal evolution of cancer populations
Cancer progresses by generating mutational diversity, which impacts
phenotypic differences in a population, depicted by varying cell color.
Variation in phenotypes leads to increased fitness in a subset of the
population, enabling survival when faced with a selective pressure,
depicted by the gray bar, and subsequent clonal expansion. This process is
repeated through multiple rounds until a highly aggressive cancer
population is generated.

The original theory behind the evolution of cancer populations can
be extended to current areas of interest in the cancer biology field. First,
the inherent variation in the population originally defined as genetic in
nature now includes epigenetic mutational events. Many cancers are can
be

driven

by

epigenetic

processes,

where

variation

in

histone

modifications can predict tumor recurrence (Seligson et al., 2005).
Furthermore, the clonal evolution theory can be applied to the metastatic
cascade as each step poses a significant impediment to cell survival and
8

division. Importantly, the final step of metastatic colonization is a highly
selective step with an estimation that less than 0.01% of cells that arrive at
a distant organ are able to form metastases (Fidler, 1970). Cancer
populations at this step would greatly benefit from an increase in
phenotypic variation, leading to higher success at this evolutionary
bottleneck (Merlo et al., 2006). Characterization of mechanisms that
generate phenotypic diversity in a cancer population has the ability to
impact understanding and the prevention of metastasis formation
broadly.

Benefit of diversity to cancer evolution
Generation of phenotypic diversity is beneficial if the phenotype
serves to increase survival and reproduction. Acquisition of the hallmarks
of cancer, such as self-sufficient growth, limitless replication potential and
evasion of apoptosis, translate into an increase in population fitness
(Hanahan and Weinberg, 2000). The initial acquisition of these features
and subsequent clonal expansion is best understood in the context of
genetic alterations. During DNA replication, spontaneous mutations can
occur in normal cells at a rate of 10 to 10 mutations per cell division
-6

-7

(Araten et al., 2005), which may lead to a rare yet significant cancerinitiating event. However, with an estimated 3-12 mutations required to
initiate cancer (Renan, 1993), it was argued that this background mutation
rate is insufficient to cause cancer (Loeb, 1991). The discovery of
mutations in DNA repair genes in hereditary nonpolyposis colorectal

9

cancer revealed a mutator phenotype that can enhance cancer progression
by increasing the rate at which mutations occur, which increases the
probability that oncogenes and tumor suppressors become genetically
altered (Fishel et al., 1993; Leach et al., 1993; Rampino et al., 1997; Renault
et al., 1996). These cancer-promoting mutations in individual cells lead to
their clonal expansion into a significant proportion of a given tumor; highthroughput sequencing of different regions within individual tumors have
revealed spatial genetic heterogeneity and evolutionary history of a cancer
as it progressed (de Bruin et al., 2014; Gerlinger et al., 2012; Navin et al.,
2011; Park et al., 2010). After iterative rounds of clonal selection and
expansion, a large number of genetic variants can exist in a population. It
is estimated that there may be approximately 1,000-3,000 mutations per
cancer cell and on the order of 10 mutations in a tumor (Bielas et al.,
12

2006), although the majority are in non-coding regions or have neutral
effect on fitness. This number of mutations observed corresponds to a 200fold higher mutational rate in cancers as compared to normal cells (Klein,
2006). This capacity to generate genetic diversity in cancer population
allows for cancer progression at a rate much higher than chance alone.
Nevertheless, any heritable change in subclonal populations that
provides a fitness advantage will enable clonal expansion and cancer
progression. Most notably, epigenetic mutations and modifications are
understood to occur more readily as compared to genetic mutations and
thus, significantly contribute to cancer progression (Baylin and Herman,
2000; Feinberg et al., 2006). Heterogeneity of histone modification patterns
has been shown to be of predictive utility for prostate cancer recurrence
10

(Seligson et al., 2005). One mechanism by which epigenetic mutations
contribute

to

population

diversity

is

through

inactivating

hypermethylation of DNA-damage response and repair genes, leading to
genetic instability (Horie-Inoue and Inoue, 2006; Weisenberger et al.,
2006). However, additional mechanisms by which epigenetic alterations
contribute to phenotypic diversity remain poorly characterized and
warrant further investigation.
From an ecological perspective, metastasis is perceived as the
colonization of a new habitat, which is dependent on the invasive ability
of the cancer cells as well as features of the new ecosystem (Merlo et al.,
2006). Ecological studies have indicated the benefit of increased species
complexity for invaders of a new habitat (Shea and Chesson, 2002), while
studies in bacteria similarly indicated that population fitness is dependent
on population diversity (Imhof and Schlotterer, 2006). Importantly,
metastasis poses numerous selective pressures that the generation of
phenotypic diversity would provide a significant fitness advantage.
Furthermore, analysis of metastases from breast, colorectal and pancreatic
cancers have revealed limited genetic alterations as compared to primary
tumors (Ding et al., 2010; Jones et al., 2008; Yachida et al., 2010),
suggesting that genetic instability may be insufficient for the acquisition of
metastatic capacity. Thus, the acquisition of metastatic capacity may in
part be driven by non-genetic mechanisms.

11

Colonization at end organ is the clinically relevant event
While metastasis involves numerous sequential steps, end organ
colonization is a critical event as it is the point at which metastatic disease
can first be clinically diagnosed. Biologically, as compared to all the
phenotypic selections required throughout metastatic cascade, end organ
colonization has experimentally been demonstrated to be one of the most
rate-limiting selective pressures. Xenograft inoculation of human cancer
cells into immune-deficient mice was the first in vivo experimental method
that enabled study of end organ colonization (Fidler, 1986; Rygaard and
Povlsen, 1969). Initial studies by Fidler observed that upon intravenous
inoculation of melanoma cells, while less than 0.1% of cells could survive
circulation, less than 0.01% of these surviving cells could produce
experimental metastases (Fidler, 1970). More recently, intermediate steps
of the metastatic cascade that include survival in circulation, arrest at a
distant organ, and extravasation were observed to occur efficiently—80%
of intravenously inoculated cells successfully extravasated. However, the
ability to form macroscopic metastases was calculated to be less than
0.02% (Luzzi et al., 1998).
This selectivity is observed analogously in patients. Among ovarian
cancer patients who received peritoneovenous shunts to treat peritoneal
ascites, effectively releasing tens of millions of cancer cells into circulation,
many never developed metastases (Tarin et al., 1984). Furthermore,
among

thousands

of

breast

cancer

patients

who

exhibited

micrometastases in their bone marrow at diagnosis, only 50% developed
overt metastases within 10 years (Braun et al., 2005). The development of
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macroscopic metastases is ultimately the cause of mortality. Given the
selectivity, clinical intervention to target metastatic colonization would
reduce the likelihood of successful therapeutic resistance and escape. The
characterization of genes and mechanisms that regulate this process
would provide significant benefit towards improving patient survival.

Objectives
The goal of this thesis is to characterize mechanisms involved in
metastatic colonization. Two approaches were performed. The first
portion of this thesis was to characterize key signaling molecules that
drive colorectal cancer metastatic liver colonization in order to develop
novel therapeutic strategies. Using an in vivo large-scale RNAi screen,
liver and red blood cell pyruvate kinase (PKLR) was identified as a driver
of liver metastatic colonization. In patients, PKLR expression was
increased in liver metastases as well as in primary tumors of patients with
metastatic disease. PKLR promoted cell survival in the tumor core during
conditions of high cell-density and oxygen deprivation through increasing
glutathione levels. PKLR was found to negatively regulate the glycolytic
activity of PKM2, a master metabolic regulator involved in controlling
glycolytic flux as well cellular glutathione levels. Glutathione appeared to
be critical for metastasis as GCLC, the rate-limiting enzyme for
glutathione synthesis, was similarly required for liver colonization and
could be therapeutically inhibited to reduce metastatic colonization. These
findings highlighted the impact of metabolic re-programming within the
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niche as metastases progress and suggested clinical potential for targeting
this pathway in colorectal cancer.
The second portion of this thesis was to characterize mechanisms
by which breast cancer cells may generate diversity as an enhancement for
clonal evolution and metastatic fitness. These mechanisms could
potentially be relevant in many cancer types as clonal evolution pertains
to all contexts of metastasis. Clonal human breast cancer subpopulations
were isolated that displayed substantial population-level phenotypic
diversity. These high variability clonal subpopulations were more
proficient at metastatic colonization—consistent with a positive role for
diversification capacity in cancer progression. Through single-cell RNAsequencing, cell-to-cell transcript expression variation was identified as a
defining feature of these subpopulations, extending to protein-level
variation. Furthermore, spliceosomal machinery was identified as a gene
set with high expression variability, suggesting a means by which
variation could be transmitted to a global level. Engineered variable
expression of spliceosomal gene SNRNP40 promoted metastatic fitness,
attributable to cells with low SNRNP40 expression. Clinically, low
SNRNP40 expression was found to be associated with metastatic relapse.
The experimental model established here could be applied to various
cancers to better understand non-genetic contributions to heterogeneity
and to study the impact of such deregulation amongst cancer populations
and their progeny.
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CHAPTER 2: PKLR Promotes Colorectal Cancer Liver Colonization by
Increasing Glutathione Levels
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2.1 Introduction

Clinical need for therapies against metastatic colorectal cancer
One cancer type that would greatly benefit from improved
therapeutic options is colorectal cancer, the third most common cancer
and the third leading cause of cancer death in America (Siegel et al., 2015).
In 2015, 132,700 new cases are expected to be diagnosed, while 49,700
individuals are expected to die from colorectal cancer. In the past few
decades, incidence and death rates have decreased largely due to
improved prevention and detection through screening. The adoption of
colonoscopy as a highly sensitive screening method has enabled both the
detection of adenomatous polyps, which can be removed to prevent
cancer development (Corley et al., 2014; Zauber et al., 2012), as well as the
detection of early-stage cancer, which allows for potentially curative
surgery and greatly improved outcomes (Nishihara et al., 2013). When
colorectal cancer is localized to the intestine, the five-year relative survival
rate is nearly 90%.
Despite the effectiveness of colorectal cancer screening, only 59% of
the US population aged fifty years and older participates in screening
measures. Because early-stage disease is often asymptomatic, those who
do not participate in these screening measures can develop undetected
disease that slowly progresses to advanced stages over the course of ten to
twenty years (Winawer and Zauber, 2002). As a result, distant disease is
found in 25% of all initially diagnosed patients and develops in 40-50% of
newly diagnosed patients (Van Cutsem et al., 2009). This translates to a
16

five-year survival of 13% for those with metastatic disease (Davies and
Goldberg, 2011; Ferlay et al., 2014).
While localized disease can be cured with surgery in the majority of
cases, metastatic disease is associated with the worst prognosis with the
liver being the most common site of distant disease. Curative surgical
resection of liver metastases may be achieved only in a minority of cases.
However, relapse after resection occurs in 75% of these patients
(Nordlinger et al., 1996), and the five-year survival rate for those who
relapse remains low at only 36% (Rees et al., 2008). Importantly, for the
majority of cases, surgery is not possible, and chemotherapy remains the
only therapeutic option to extend life.
Current chemotherapy regimens are based on 5-fluorouracil (5-FU),
a pyrimidine analog that was introduced and adopted for clinical use in
the 1950s (Heidelberger et al., 1957). 5-fluorouracil was found to
incorporate into DNA during replication and inhibit RNA synthesis,
leading to decreased cell growth and proliferation. This growth-inhibitory
effect was first observed in solid tumors implanted in mice, and rapidly
was translated to clinical responses in patients with a variety of cancer
types (Curreri et al., 1958). Leucovorin (LV), a vitamin that inhibits
thymidylate synthase, was added to enhance 5-fluorouracil efficacy (Poon
et al., 1989). While 5-FU/LV showed significant efficacy in prolonging life,
this combination exhibited no major impact on overall survival (1992).
Alkylating agents such as oxaliplatin and irinotecan were included
more recently, forming the current cytotoxic chemotherapy combination
regimens, FOLFOX (5-FU/LV/oxaliplatin) (de Gramont et al., 2000) and
17

FOLFIRI (5-FU/LV/irinotecan) (Saltz et al., 2000). Despite significant
effects on progression-free survival time, modest effects on overall
survival time, and nuanced changes to timing and delivery strategies,
only 10% of patients live beyond five years since metastases ultimately
lose responsiveness to these therapies (Davies and Goldberg, 2011).
Molecularly targeting therapies such as the VEGF inhibitor bevacizumab
and EGFR inhibitor cetuximab have marginally improved survival by
delaying progression, though patients eventually do succumb to the
disease (Davies and Goldberg, 2011). At this point, the current
chemotherapy regimen mainly serves a palliative role to extend survival
and improve quality of life (Glimelius et al., 1994). For a therapy to have
curative potential, strategies specific against metastasis-promoting
phenotypes must be developed to limit progression at rate-limiting steps
where resistance will be less readily acquired. With metastatic disease in
the liver being the life-limiting aspect for late-stage colon cancer patients,
characterization of metastatic colonization and progression would provide
significant advances towards the development of more effective therapies.

Mechanisms of colorectal cancer progression
Colorectal cancer arises through a progression of mutational and
transformative events on epithelial tissue that allows for increasing
aggressiveness. The initiating event is often the acquisition of genomic
instability. Genomic instability can arise by DNA hypermethylation in
fifteen percent of sporadic cases, while germ-line mutations in DNA
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repair machinery predisposes patients to a high likelihood of colorectal
cancer (Markowitz and Bertagnolli, 2009). The most common mode of
genomic instability is through chromosomal instability. This early genetic
deregulation

allows

characteristic

of

for

hyperplastic

adenomatous

polyps.

growth

and

Uncontrolled

proliferation,
growth

and

continued genetic instability leads to inactivating mutations in critical
tumor-suppressor genes such as APC, p53, and SMAD4 and activating
mutations in oncogenes such as K-RAS, BRAF, and PIK3CA (Markowitz
and Bertagnolli, 2009)(Illustration 3.1). These genes regulate cellular
processes that when deregulated, help define fundamental aspects of
cancer regardless of cancer type, which include self-sufficiency in growth
signaling, resistance to anti-growth signals, evasion of apoptosis, and
limitless replicative potential (Hanahan and Weinberg, 2000). Continued
evolution of cancer populations led to even more aggressive phenotypes,
eventually progressing into invasive and disseminated disease. The model
of progressive acquisition of cancer-promoting mutations is supported by
the observed genetic profile of primary tumors of different grades (Fearon
and Vogelstein, 1990; Vogelstein et al., 1988). Progression into metastasis
is understood to be an evolutionary process whereby clonal selection of
cancer cells with the highest fitness at a phenotypic level allows for
population advancement (Nowell, 1976; Talmadge and Fidler, 2010).
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Illustration 2.1: Genetic progression of colorectal cancer
Progression of colorectal cancer is shown with known genetic alterations
that contribute to cancer development. MSI = microsatellite instability,
CIN = chromosomal instability
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Metastatic colonization of the liver
To clinically impact colorectal cancer, the process of liver
colonization must be better characterized (Talmadge and Fidler, 2010;
Valastyan and Weinberg, 2011). Metastatic colonization, the formation of
macroscopic metastases, has been observed to be a significant rate-limiting
step during metastatic liver growth (Luzzi et al., 1998). This selective
pressure may be in part attributable to the liver microenvironment, which
is marked by hypoxic regions, a unique circulatory architecture, and
significant metabolic activity (Jungermann and Kietzmann, 1996). The
genes and pathways most suitable for therapeutic inhibition would be
those whose expression is necessary for colonization events. Furthermore,
it remains unclear whether cancer cells utilize different mechanisms for
early or late colonization events (Sullivan and Christofk, 2015). Early
metastatic colonization can be achieved through utilization of liverderived energetic molecules to enhance survival upon arrival in the
hypoxic, nutrient-poor liver microenvironment (Loo et al., 2015).
However, therapeutics that target early colonization are only useful for
prevention of metastatic nodule formation. Late colonization events,
which contribute to the continued progression of macro-metastases,
represent a stage with significant clinical need given that patients who
develop liver metastases exhibit a poor prognosis and that approximately
twenty percent of patients initially present with distant metastatic disease
(Siegel et al., 2014). Nevertheless, both early and late metastatic
colonization remain poorly characterized and must be systematically
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approached for the development of biologically relevant therapeutic
strategies.

Functional genomics in cancer
The identification of the key regulators of metastatic colonization
can benefit from a systematic, functional approach. Classical genetic
screening

approaches

utilized

chemical

and

transposon-based

mutagenesis, allowing for the unbiased identification of genes responsible
for the biological process of interest (Boutros and Ahringer, 2008).
However, the process of identification and characterization of the genes of
interest is time-consuming and laborious. Additionally, complex
phenotypes and the large size of the mammalian genome render classical
screening approaches infeasible (Boutros and Ahringer, 2008). The
discovery and application of RNAi for screening purposes has enabled
large-scale screening in mammalian systems (Elbashir et al., 2001) (Root et
al., 2006). RNAi screens in cancer were first applied to identify essential
genes for cancer cell proliferation and survival (Luo et al., 2008; Schlabach
et al., 2008; Silva et al., 2008; Whitehurst et al., 2007). More recent
applications have brought this screening technique to cancer progression
in vivo, enabling the characterization of pathological and developmental
processes under more physiological conditions (Beronja et al., 2013; Zuber
et al., 2011). Utilization of large-scale loss-of-function screens has enabled
the identification and characterization of novel regulators of disease
processes.
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2.2 Identification of kinases that promote liver colonization

Large-scale in vivo shRNA screen for promoters of liver colonization
To molecularly study colorectal cancer colonization in the liver, a
large-scale in vivo shRNA screen was performed to identify key regulatory
genes (Figure 2.1). Three human colon cancer cell lines, LS174T, SW620
and WiDr, representing the mutational spectrum commonly seen in
patients (Kras wild-type/mutant, Braf wild-type/mutant, MSS/MSI),
were transduced with shRNA-encoding lentiviral particles. Ten subpools
were used in total that included 54,591 total hairpins targeting 14,095
human genes. Cells were transduced at a low titer to ensure only a single
shRNA would be incorporated into a cell. These transduced cell
populations were then divided into three fractions. The first fraction was
saved as a reference population to account for shRNA inserts initially
present. A second fraction was inoculated into immuno-deficient mice by
direct liver injection for the selection of cells capable of colonizing the
liver. The third fraction was grown in culture to select for cells capable of
basal growth and survival. Once tumors had developed in the liver, these
tumors were harvested, and all three fractions were processed to isolate
genomic DNA and amplify the incorporated shRNA inserts for highthroughput sequencing. Sequencing allowed for quantification of shRNA
inserts and calculation of relative depletion of shRNAs from tumors and
cultured cells. Loss of shRNA representation from the tumors would
suggest that depletion of the targeted genes suppressed the ability of
colon cancer cells to colonize the liver.
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Figure 2.1: Large-scale shRNA screen for promoters of liver metastasis
Schematic of pooled shRNA library dropout screen. Colon cancer cell lines
were transduced with an shRNA library and subject to direct liver
injections (top), growth in culture (bottom), and reference sample (T ,
0

middle). Samples were processed to allow for sequencing of shRNA
inserts to allow for identification of genes that promote liver colonization
as well as genes that promote population growth.
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Analysis of shRNA profiling revealed significant depletion of
shRNAs across all cell lines in both tumors and cultured cells (Figure 2.2).
A correlation matrix for all profiled samples revealed that for the majority
of samples, liver tumor profiles displayed greater similarity despite
differing parental cell line origins (Figure 2.3). To identify broadly
relevant metastasis regulators, genes were considered as putative
promoters of liver colonization if at least two shRNAs targeting a given
gene were depleted in tumors derived from all three cell lines and both
independent transductions. This analysis resulted in 556 candidate
promoters of liver colonization (Figure 2.4). Using similar criteria, 719
genes appeared to be required for survival in cultured cells, while 187
genes were in common to both cultured cells and tumor cells (Figure 2.4).
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Figure 2.2: Depletion of shRNAs from large-scale shRNA screen for
promoters of liver metastasis
Overview of shRNA depletion in liver tumors (a) and cultured cells (b).
shRNAs were ranked based on peak median absolute deviation
normalized z-score of log (Tumor/T ) or log (Passaged/T ). shRNAs absent
2

0

2

0

in both tumor replicates or cultured cells are in black. P-values for absent
shRNAs were derived by bootstrapping with 1000 random samplings.
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Figure 2.3: Correlation matrix of shRNA screen samples
Correlation matrix of shRNA-depletion profiles of samples using
Spearman’s correlation coefficient. Clustering was performed in R using
Euclidean distance and complete agglomeration method. SW = SW620, LS
= LS174T, Wi = WiDr.
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Figure 2.4: Genes with two or more shRNAs absent from screen samples
Summary of absent shRNAs and gene hits from tumor (a) and cultured
cells (b) in each cell line and in common to all cell lines. Percentage of total
population is indicated in parentheses. (c) Overlap between gene hits
scored in tumors and those scored in culture.
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To confirm that the analyzed shRNAs were effective in suppressing
liver colonization, a secondary library was generated using top-scoring
shRNAs that targeted the 556 genes. These top-scoring shRNAs as well as
20 control shRNAs were cloned into the plko.1 expression vector and
pooled to allow for equal representation in the library. This library was
transduced into a highly metastatic in vivo-selected colon cell line, LSLVM3b (Loo et al., 2015). These populations were then subjected to the
experimental procedures performed for the primary large-scale screen.
This experiment revealed that these shRNAs were significantly depleted
from tumors, confirming the technical efficacy (Figure 2.5). To better rank
the candidate hits from the screen, genes were scored from the primary
large-scale liver colonization screen by applying the RIGER algorithm,
which ranks genes based on the number and relative depletion of
targeting shRNAs and thus accounts for differences in the number of
shRNAs per gene (Luo et al., 2008). These scores were used to generate
gene percentile scores, providing a continuous scale to assess relative
importance of genes. As expected, the top 556 candidate genes were
significantly enriched among the top percentile scores, providing
confidence in the candidate liver colonization gene list (Figure 2.5).
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Figure 2.5: Validation of scoring shRNAs and final scoring method
(a) Distribution of shRNA depletion in tumors from secondary library
using a scoring shRNA targeting each of the 556 top genes. (b)
Distribution of 556 top genes as scored by RIGER and ranked by gene
percentile.

Identification of PKLR as a kinase required for liver colonization
Of the top-scoring 556 genes from the primary screen, kinases,
which are known to mediate most of the signal transduction in eukaryotic
cells (Manning et al., 2002) were focused on to allow for the identification
of critical regulatory mechanisms. The top-scoring kinases from the
RIGER gene ranking included many known regulators of colorectal cancer
progression including IGF1R (Reinmuth et al., 2002) and DDR2 (Badiola et
al., 2011), which, consistent with previous studies, displayed high gene
percentile scores in the screen performed in cultured cells, indicative of
roles in in vitro population growth (Figure 2.6). Surprisingly, one of the
top-scoring genes was liver and red blood cell pyruvate kinase (PKLR),
which had been commonly believed to be expressed only in liver, kidney,
and red blood cells (Luo and Semenza, 2012). Interestingly, PKLR
displayed a low gene percentile score under culture conditions,
suggesting a specific requirement for this gene during liver colonization.
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Figure 2.6: Gene percentile scores of top kinases from large-scale
shRNA screen
Kinases from top 556 candidate promoters were ranked by RIGER gene
percentile score in liver tumor and cell culture large-scale screens.

Fuctional validation of PKLR as promoter of metastatic liver colonization
To confirm these findings and account for potential off-target
effects from the targeting shRNAs in the primary screen, LS174T cell lines
were generated with additional independent PKLR-targeting shRNAs not
previously used in the primary screen (Figure 2.7). PKLR expression was
adequately depleted to the levels of 13% & 17% of control. Importantly, in
concordance with the in vivo screen results, PKLR-depleted cells were
significantly less effective than control cells in colonizing the liver
following direct liver inoculation (Figure 2.7). Additionally, in vitro
proliferation assays confirmed that PKLR depletion did not reduce
population growth in culture and also did not reduce subcutaneous tumor
growth (Figure 2.8).
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Figure 2.7: PKLR promotes liver colonization
(a) PKLR depletion as measured by quantitative RT-PCR in LS174T cells.
(b) 5x10 LS174T cells were inoculated by direct liver injection, and liver
5

colonization was measured by ex vivo bioluminescence after 20 days.
Representative liver bioluminescence and gross histology are shown
(n=6). P-values were derived using one-sided Mann Whitney test.

32

Figure 2.8: PKLR does not promote population growth in culture or
subcutaneous tumor growth
(a) 5x10 LS174T cells were seeded in triplicate and viable cells were
4

counted by trypan blue exclusion after 5 days under recommended cell
culture conditions. Data shown is from three independent experiments.
(b) 10 LS174T cells were injected into mice subcutaneously and tumor
6

volume was measured over time (n=6).

To validate this colonization defect in the context of metastasis,
additional cell lines were generated with additional shRNAs targeting
PKLR. In the highly metastatic LS-LVM3b cell line, PKLR expression was
depleted to 9% of control, while in the SW620 cell line, PKLR expression
was depleted to 58% and 42% of control (Figure 2.9). These cells were then
inoculated via portal circulation to assess metastatic capacity upon
hematogenous arrival in the liver. PKLR-depleted cells exhibited
significantly decreased liver metastatic colonization capacity in metastasis
assays (Figure 2.9). These results revealed PKLR to promote metastatic
liver colonization of colon cancer cells.
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Figure 2.9: PKLR promotes metastatic liver colonization
PKLR depletion as measured by quantitative RT-PCR in LS-LVM3b (a)
and SW620 cells (c). 5x10 LS-LVM3b (b) and SW620 (d) cells were
5

inoculated by portal circulation injection and metastatic colonization was
measured by liver bioluminescence after 20 days (n=14) for LS-LVM3b
and 35 days (n=8) for SW620. Representative mouse bioluminescence,
liver bioluminescence and gross histology are shown. P-values were
derived using one-sided Mann Whitney test.
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To further characterize the role of PKLR in colonization, PKLR was
assessed for whether it promoted colonization in the setting of the
primary tumor before cancer cell dissemination. Cells were inoculated
into the cecal wall of mice to model primary colorectal cancer tumor
growth. PKLR depletion did not affect tumor growth under these
conditions (Figure 2.10), indicating that PKLR provides an advantage
selectively to metastatic growth.

Figure 2.10: PKLR does not promote primary tumor growth
10 LS174T cells were inoculated by cecal injection and tumor growth was
6

monitored by in vivo bioluminescence over time (n=5). Representative
mouse bioluminescence at final time point are shown on the right.
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2.3 Clinical relevance of PKLR expression

PKLR expression in normal colon and colon cancer tissue
In mammalian cells, pyruvate kinase is encoded by four isozymes:
M1 (PKM1), M2 (PKM2), liver (PKL) and red blood cell (PKR). While the
M1, L and R isozymes are described to exhibit tissue-specific expression,
the pyruvate kinase M2 isoform is highly expressed across cancer types
(Mazurek et al., 2005). Pyruvate kinase L and R have only been described
in their respective tissues to promote glycolysis, catalyzing the final ratelimiting step, which involves the transfer of a phosphate group from
phosphoenolpyruvate (PEP) to ADP, generating pyruvate and ATP.
Although PKLR had originally been described to be expressed solely in
liver, kidney and red blood cells (Imamura and Tanaka, 1972), PKL
expression has also been observed in epithelial cells in the intestinal
epithelium of rats (Domingo et al., 1992; Osterman and Fritz, 1974).
Analysis of the Human Protein Atlas data (Uhlen et al., 2010) revealed
PKL mRNA expression in normal colon tissue and PKLR protein
expression in normal colonic glandular tissue and colorectal cancer
tumors (http://www.proteinatlas.org, Figure 2.11).
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Figure 2.11: PKLR is expressed in normal colon and colon cancer tissue
(a) RNA-sequencing read density at PKLR locus from normal colon tissue.
PKL-specific exon is indicated with dashed box. (b) PKLR protein
expression as measured by immunohistochemistry in normal colon and
colorectal cancer tissue. Scale bar is 100um.
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PKLR expression is associated with clinical liver metastasis
To determine whether PKLR expression levels are associated with
liver metastasis, PKLR transcript levels were compared in patient samples
of primary tumors and liver metastases. Samples were obtained from
patients at MSKCC to compare PKLR transcript levels in patient primary
tumor and liver metastasis samples. In 70 samples, PKLR mRNA was
significantly up-regulated in liver metastases relative to primary tumors
(Figure 2.12c). This up-regulation was also observed in multiple
independent datasets of unmatched (Figure 2.12a-b) and matched (Figure
2.12d-e) colorectal cancer patient samples (Ki et al., 2007; Kikuchi et al.,
2013; Kim et al., 2014; Matsuyama et al., 2010; Sheffer et al., 2009; Stange et
al., 2010; Watanabe et al., 2011). These samples were from a total of 311
patients. Additionally, in primary tumors, increased PKLR expression was
associated with the presence of metastatic disease as well as the
development of liver metastases (Figure 2.13). These tumors totaled 284 in
sum. Taken together, PKLR expression in human samples is consistent
with a positive role for PKLR in the development of liver metastasis and
in agreement with functional experimental data.
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Figure 2.12: PKLR expression is increased in human liver metastases
PKLR expression as measured by microarray (a), RNA-sequencing (b),
and quantitative RT-PCR (c) in unmatched primary and liver metastasis
tumors as shown by box plots. P-values were derived using one-sided
Mann Whitney test unless otherwise indicated. Error bars represent SEM.
(d)(e) PKLR expression as measured by microarray in matched primary
and liver metastasis tumors. Increase in PKLR expression is indicated in
red; decreased expression is indicated in gray. P-values were derived
using paired one-sided t-test. *=P<0.05, **=P<0.01, ***=P<0.001
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Figure 2.13: PKLR expression is increased in primary tumor samples
from patients with metastases
(a)(b) PKLR expression as measured by microarray in primary tumors of
patients with or without metastases present at time of sampling. (c) PKLR
expression as measured by microarray in primary tumors of patients who
were monitored over time for the development of liver metastases. Pvalues were derived using one-sided Mann Whitney test unless otherwise
indicated. Error bars represent SEM. *=P<0.05
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2.4 Cellular characterization of PKLR function

PKLR promotes cell survival during colonization in vivo
To characterize how PKLR promotes metastasis at the cellular level,
two possibilities were considered. PKLR could function to promote cell
growth and proliferation, or PKLR could function to prevent cell death.
Since PKLR depletion had no effect on subcutaneous tumor growth or
primary tumor growth (Figures 2.8, 2.10), PKLR knockdown cells were
assessed for cell death in vivo. To assess cell death, an in vivo caspase-3/7dependent bioluminescence reporter (Hickson et al., 2010) was used to
measure apoptotic cell burden during metastatic liver growth. At early as
well as at late time points, apoptosis was significantly increased in PKLR
knockdown cells (Figure 2.14). Calculation of cumulative apoptotic
burden over time revealed a significantly elevated rate of apoptosis
(Figure 2.14), suggesting that PKLR is required for continuous metastatic
cell survival.
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Figure 2.14: PKLR knockdown leads to increased cancer apoptosis
(a) 5x10 SW620 cells were inoculated by portal circulation injection and
5

apoptotic cell burden in the liver was monitored using DEVD-luciferin
bioluminescence relative to live cell bioluminescence over time (n=5). Pvalues were derived using one-sided Student’s t test. (b) Cumulative
apoptotic/live cell burden over time was determined by calculating the
area under the curve for each mouse. Linear regression lines are shown. Pvalues were derived using ANCOVA testing for difference in slope.
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To confirm these findings, livers were extracted and processed to
visualize apoptotic markers in tumor nodules. PKLR-depleted cells
exhibited significantly fewer tumor nodules per liver (Figure 2.15),
confirming our original assessments by gross histology. Interestingly,
while tumor nodules generated from control cells appeared to be highly
cellular, the majority of PKLR-depleted tumor nodule cores appeared
devoid of cells and composed of extracellular cleaved caspase-3 (Figure
2.15). While the reduced number of tumor nodules indicates the
importance of PKLR in early colonization, enhanced apoptosis in tumor
cores suggested a pathophysiological requirement for PKLR function
during later stages of metastatic colonization.
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Figure 2.15: PKLR knockdown metastatic nodules display increased
apoptosis in tumor core
(a) 5x10 SW620 cells were inoculated by portal circulation injection; after
5

28 days, livers were resected, and nodules per liver section was quantified
(n=4). The average of three liver sections for each mouse was used. (b) For
each liver, proportion of the indicated nodule type is shown. P-values
were derived using two-sided Fisher’s exact test on total nodule count for
each PKLR shRNA compared to shControl. (c) Representative images of
nodule types. Luciferase and human Vimentin were used to label cancer
cells. Inset shows higher magnification. Scale bars = 50um.
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PKLR promotes cell survival under hypoxia and high cell density in vitro
The tumor core represents a distinct microenvironment with
limited nutrient supply, unique stromal composition, and altered cell-tocell architecture (Quail and Joyce, 2013). Liver metastases are susceptible
to stress-induced apoptosis (Bao et al., 2004) and demonstrate variable
angiogenic capacity (Vermeulen et al., 2001), suggesting that cancer cells
farther from vasculature may be especially sensitive to nutrient and
oxygen deprivation. PKLR may be required for survival when cancer cells
are subject to cellular stressors specific to the tumor core. To identify
potential stressors, PKLR knockdown cells were grown under various
conditions in vitro and were found to exhibit no survival defects under
physiologic levels of glucose, hypoxia (1% O ), anoxia (<0.01% O ), high
2

2

cell density, or low pH (Figure 2.16). Moreover, PKLR-depleted cells did
not exhibit defects in well-established pro-metastatic phenotypes
including Matrigel invasion capacity, anchorage-independent growth, and
migration (Figure 2.16).
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Figure 2.16: PKLR does not promote survival under various in vitro
conditions
Cells were seeded in triplicate under the following conditions: (a) 10 cells
5

in 5.6mM glucose for 5 days, (b) 10 cells in 5.6mM glucose & hypoxia for 5
5

days, (c) 10 cells in anoxia for 3 days, (d) 10 cells seeded at a density of
6

6

1000 cells/mm for 3 days, (e) 10 cells in media buffered at pH 6.6 for 5
2

5

days, (f) 25x10 cells in quadruplicate in invasion chambers and were
3

allowed to invade for 48 hours, (g) 5x10 cells seeded in soft agar for 14
3

days. Data shown is from three independent experiments. (h) 10 cells
6

seeded overnight and scratched using a pipette tip the next day. Cells
were seeded in duplicate and imaged daily.
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While individual stressors elicited no phenotypic defect alone, the
tumor core features multiple stressors that simultaneously impact cancer
cells. To better recapitulate the microenvironment in the tumor core, cells
were concurrently seeded at high cell density and in hypoxia. Under these
conditions, PKLR knockdown populations displayed reduced survival—
decreased number of live cells and concurrently increased number of dead
cells (Figure 2.17). To characterize whether the survival defect occurs
continuously or whether nutrient depletion led to a population collapse,
cells were assayed daily for viability under high cell density and hypoxia.
Cells with reduced PKLR expression began to display a survival defect
after as early as one day under these conditions, suggesting that the effect
is continuous (Figure 2.17). Given the increased apoptosis rate observed in
PKLR-depleted tumors, cells were assessed for apoptosis and necrosis by
flow cytometry after one day under concurrent high cell-density and
hypoxia. PKLR depleted cells exhibited fewer live cells, greater proportion
of early apoptotic cells, and significantly greater proportion of late
apoptotic cells under this condition (Figure 2.17). These results indicated
that PKLR functions to enhance cell survival under cell-dense, hypoxic
conditions,

appropriately

simulating

pertaining to metastatic growth in the liver.

47

pathophysiological

features

Figure 2.17: PKLR promotes survival under conditions of hypoxia and
high cell density
(a) 10 LS174T cells were seeded in triplicate at a density of 1000 cells/mm
6

2

and were allowed to grow for 5 days in 1% O . Live and dead cells
2

discriminated using trypan blue. Data shown is from four independent
experiments. (b) 10 LS174T cells were seeded in triplicate at a density of
6

1000 cells/mm and were allowed to grow in 1% O Live cells were
2

2.

quantified using trypan blue exclusion. Data shown is from three
independent experiments. 10 LS174T (c) and SW620 (d) cells were seeded
6

at a density of 1000 cells/mm and were assessed for apoptosis after 24
2

hours in 1% O . P-values were derived using one-sided Student’s t test.
2
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2.5 Molecular characterization of PKLR function

Identification of binding partners of PKL and PKR
Interestingly, the in vitro survival defect of PKLR-depleted cells was
observed using cell culture media supplemented with excess pyruvate,
which can be readily imported into cells (Garcia et al., 1994)—arguing
against the canonical glycolytic function of PKLR in these colon cancer
cells. To determine whether PKLR could be functioning non-canonically,
independent of its pro-glycolytic role, PKL and PKR binding partners
were identified in colorectal cancer cells using tagged proteins for coimmunoprecipitation

experiments

since

commercial

and

custom

antibodies were inadequate for the recognition of endogenous PKLR
proteins in cell lysates. Immunoprecipitation of PKL and PKR followed by
mass spectrometry revealed similar protein binding profiles and binding
to many glycolytic enzymes (Figure 2.18, Table 2.1, Table 2.2), consistent
with the role of pyruvate kinase in a glycolytic enzyme complex that
allows for efficient lactate production (Mazurek, 2011).
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Figure 2.18: Mass spectrometry analysis of PKL & PKR coimmunoprecipitated proteins
LC-MS/MS

ion

scores

of

FLAG-PKL

and

FLAG-PKR

co-

immunoprecipitated proteins relative to empty vector in LS-LVM3b.
Pearson’s correlation coefficient is shown.
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Table 2.1: Top gene sets scored by Gene Set Enrichment Analysis of
FLAG-PKL binding partners as measured by mass spectrometric
quantification

Table 2.2: Top gene sets scored by Gene Set Enrichment Analysis of
FLAG-PKR binding partners as measured by mass spectrometric
quantification
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Interestingly, one of the most abundant binding partners identified
was PKM, with multiple peptides matching specifically to the M2 isoform
(Table 2.3, Figure 2.19)—the predominant isoform observed in colorectal
cancer tissue and the only isoform observed to be expressed in the cell
lines used (Bluemlein et al., 2011; Christofk et al., 2008a; Thangaraju et al.,
2009). Immunoprecipitation of tagged PKL or PKR revealed an association
with endogenous PKM2 (Figure 2.19). Moreover, immunoprecipitation of
endogenous PKM2 revealed PKM2 to associate with endogenous PKL
(Figure 2.19). This suggested the formation of a pyruvate kinase hybrid
complex (Saheki et al., 1978).

Table 2.3: PKM2-specific peptides as measured by mass spectrometric
quantification
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Figure 2.19: PKL binds to PKM2 in colon cancer cells
(a) Cell lysates from LS-LVM3b cells with indicated overexpression
constructs were subjected to immunoprecipitation using anti-FLAG beads
followed by LC-MS/MS. Protein peptide spectrum matches as compared
to label free quantitation protein enrichment (relative to empty vector
immunoprecipitation) is shown. (b) Cell lysates from LS-LVM3b cells
were subjected to immunoprecipitation using anti-FLAG beads followed
by western blot analysis. (c) Cell lysates from LS174T cells were subjected
to immunoprecipitation using anti-HA beads followed by western blot
analysis. 20 ng of recombinant PKL (rPKL) and PKR (rPKR) were
analyzed as controls (dashed border).
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PKLR negatively regulates PKM2 pyruvate kinase activity
Given the differing biochemical properties of pyruvate kinase
isozymes and the tetrameric structure required for maximal enzymatic
activity (Mazurek, 2011), PKL could function to alter PKM2 pyruvate
kinase activity. To test this hypothesis, PKLR-depleted cells were grown in
cell-dense, hypoxic conditions and were subject to immunoprecipitation of
PKM2 complexes. PKM2 complexes isolated from PKLR-depleted cells
exhibited enhanced pyruvate kinase activity relative to control cells
(Figure 2.20), indicating that PKLR negatively regulates PKM2 pyruvate
kinase activity. Additionally, whole cell lysates from PKLR-depleted cells
displayed an increase in total pyruvate kinase activity as well as decreased
phosphoenolpyruvate-to-pyruvate

ratio,

consistent

with

decreased

reaction substrate and increased reaction product driven by increased
catalytic activity, following incubation under hypoxic, cell-dense
conditions (Figure 2.20). These findings revealed that in colon cancer cells,
PKLR expression can be utilized to negatively regulate PKM2 pyruvate
kinase activity and deregulate metabolism to allow for cancer progression.
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Figure 2.20: PKLR negatively regulates PKM2 pyruvate kinase activity
(a) Immunoprecipitated PKM2 complexes from LS174T cells, subjected to
16 hours in high cell-density and hypoxia, were assayed for pyruvate
kinase activity. Activity was normalized to immunoprecipitated HAPKM2 as measured by western blotting. Data shown is from three
biological replicates. P-value was derived using two-sided Student’s t test.
Pyruvate kinase activity was measured from LS174T (b) and SW620 (c)
cell lysates after 24 hours under hypoxic, cell-dense conditions. Activity
was normalized to live cells. P-values were derived using one-sided
Student’s t test. Data shown is from six biological replicates and two
independent experiments. (d) Pyruvate levels and phosphoenolpyruvate
(PEP) levels were measured from LS174T cell lysates after 24 hours under
hypoxic, cell-dense conditions. P-value was derived using one-sided t-test.
Each experiment was performed in triplicate. Data shown is from four
independent experiments.
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PKLR increases glutathione levels
PKM2 is essential for aerobic glycolysis observed in cancer cells,
which

leads

to

preferential

lactate

production

and

decreased

mitochondrial metabolism (Christofk et al., 2008a). Previous studies have
demonstrated an advantage conferred by decreasing PKM2 activity in
cancer cells, namely the diversion of metabolic flux towards anabolic
pathways, which promote biosynthetic processes (Christofk et al., 2008b;
Lunt et al., 2014) and intracellular reducing power under oxidizing
conditions through the pentose phosphate pathway (Anastasiou et al.,
2011). Because PKLR knockdown cells demonstrated no proliferative
defect under oxygenated conditions (Figure 2.8) as seen with impaired
biosynthetic processes, PKLR knockdown cells were assessed for
depletion of intracellular glutathione, the main cellular antioxidant
(Franklin et al., 2009), under hypoxic, cell-dense conditions. Indeed, PKLR
knockdown cells demonstrated decreased glutathione levels (Figure 2.21).
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Figure 2.21: PKLR increases glutathione levels
Glutathione levels were measured using ThiolTracker from LS174T (a)
and SW620 (b) cell lysates after 24 hours under hypoxic, cell-dense
conditions. P-values were derived using one-sided t-test. Data shown is
from three biological replicates.

57

Restoration of glutathione levels in PKLR-depleted cells rescues metastatic
survival
To confirm glutathione depletion is responsible for the cell survival
defect, supplementation with molecules that can restore glutathione levels
should rescue cell survival under hypoxic and cell-dense conditions as
well as metastatic colonization. PKLR knockdown cells incubated in
hypoxic and cell-dense conditions were supplemented with the
antioxidant N-acetyl cysteine (NAC), a pro-drug to a glutathione
precursor, and glutathione-monoethylester (GSH-MEE), a membranepermeable glutathione analog as glutathione does not readily cross the cell
membrane. Treatment with these compounds rescued cell viability and
decreased apoptosis in PKLR-depleted cells in vitro (Figure 2.22).
Consistent with these in vitro findings, treatment of mice bearing PKLR
knockdown cells with NAC in the drinking water partially rescued
metastatic liver colonization and nearly completely restored the apoptosis
rate to the levels of control cells (Figure 2.23).
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Figure 2.22: Restoration of glutathione levels rescues cell survival in
vitro
LS174T (a) and SW620 (b) cells were assayed after 24 hours under
hypoxic, cell-dense conditions for live and apoptotic cells by flow
cytomentry. N-acetyl cysteine (NAC) and glutathione-monoethylester
(GSH-MEE) were added to culture medium. P-values were derived using
one-sided t-test. Data shown is from three biological replicates.
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Figure 2.23: Restoration of glutathione levels rescues metastatic survival
(a) 5x10 SW620 cells were inoculated by portal circulation injection, mice
5

were treated with NAC or control drinking water, and metastatic
colonization was measured by liver bioluminescence after 35 days (n=5).
P-values

were

derived

using

one-sided

Mann

Whitney

test.

Representative mouse bioluminescence, liver bioluminescence and gross
histology are shown. (b)(c) Apoptotic cell burden was monitored by
DEVD-luciferin

liver

bioluminescence

relative

to

total

live

cell

bioluminescence over time. Day 14 is shown in (c). (d) Cumulative
apoptotic/live cell burden over time was determined by calculating the
area under the curve for each mouse. Linear regression lines are shown. Pvalues were derived using ANCOVA testing for difference in slope.
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2.6 Therapeutic inhibition of glutathione synthesis

GCLC expression is associated with liver metastasis in patients
Given the susceptibility of liver metastases to glutathione
depletion, glutathione synthesis might serve as a critical pathway utilized
for metastatic progression. GCLC, the catalytic subunit of glutamate
cysteine ligase, is responsible for the rate-limiting reaction of glutathione
synthesis (Griffith, 1999) and thus, would be an appropriate molecular
target for therapeutic inhibition. To determine whether GCLC may play a
role in colorectal cancer metastasis to the liver, transcript expression levels
were analyzed in patient samples. GCLC expression levels were found to
be significantly higher in human colorectal cancer liver metastases relative
to primary tumors (Figure 2.24).
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Figure 2.24: GCLC expression is increased in human liver metastases
GCLC expression as measured by RNA-sequencing (a) and microarray (b)
in unmatched primary and liver metastasis tumors as shown by box plots.
P-values were derived using one-sided Mann Whitney test. (c) GCLC
expression as measured by microarray in matched primary and liver
metastasis tumors. Increase in GCLC expression is indicated in red;
decreased expression is indicated in gray. P-values were derived using
paired one-sided t-test.
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Functional validation of GCLC as promoter of liver metastasis
To determine if GCLC is functionally required for metastasis in a
manner consistent with the cell survival function of PKLR, functional
studies were performed using cells depleted of GCLC by RNAi. GCLC
expression was depleted to 27% & 13% of control in LS174T cells and 41%
& 26% of control in SW480 cells (Figure 2.25). Functional studies in vitro
revealed GCLC to be required for cell survival under hypoxia and celldense conditions (Figure 2.25). Functional studies in vivo revealed GCLC
to be required for metastatic liver colonization and to suppress cancer cell
apoptosis (Figure 2.26), consistent with the observed phenotypes seen
with PKLR knockdown.
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Figure 2.25: GCLC promotes survival under conditions of hypoxia and
high cell density
GCLC knockdown as measured by qRT-PCR in LS174T cells (a) and
SW620 (c). 10 LS174T (b) and SW480 (d) cells were seeded at a density of
6

1000 cells/mm and were assessed for apoptosis after 24 hours in 1% O . P2

2

values were derived using one-sided Student’s t test.
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Figure 2.26: GCLC promotes metastatic liver colonization
5x10 LS174T (a) and SW480 (c) cells were inoculated by portal circulation
5

injection

and

bioluminescence

metastatic
after

21

colonization
days

was

(LS174T)

measured

or

30

days

by

liver

(SW480).

Representative mouse bioluminescence, liver bioluminescence and gross
histology are shown. n=5. (b) DEVD-luciferin bioluminescence relative to
live cell bioluminescence was measured in the liver at day 7 (n=5). Pvalues were derived using one-sided Student’s t-Test.
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Small molecule inhibition of GCLC suppresses metastasis
The findings that GCLC promotes metastatic colonization
suggested that small molecules that block glutathione synthesis may
exhibit metastasis-suppressive effects (Schulze and Harris, 2012). To test
this hypothesis, colon cancer cells were first inoculated into the portal
circulation of mice, and then L-buthionine-(S,R)-sulfoximine (BSO), a
small molecule inhibitor of GCLC (Griffith, 1982), was added to the
drinking water. Therapeutic delivery of BSO suppressed metastatic
colonization and increased cancer cell apoptosis in colon cancer cell lines
(Figure 2.27). Additionally, BSO suppressed metastasis of a primary cell
line recently obtained from a patient’s colorectal cancer tumor and
passaged in mice (Figure 2.28). These results highlight the importance of
cancer cell glutathione levels for metastatic survival in the liver and
identify this metabolic pathway as a viable therapeutic target.
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Figure 2.27: BSO suppresses metastasis in colon cancer cell lines
5x10 LS174T (a) and SW480 (c) cells were inoculated by portal circulation
5

injection, and mice were provided BSO in drinking water. Metastatic
colonization was measured by liver bioluminescence after 28 days
(LS174T) or 35 days (SW480). Representative mouse bioluminescence,
liver bioluminescence and gross histology are shown. n=5. (b) DEVDluciferin bioluminescence relative to live cell bioluminescence was
measured in the liver at day 7 (n=5). P-values were derived using onesided Student’s t-Test.
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Figure 2.28: BSO suppresses metastasis in primary colon cancer cell line
7.5x10 CLR1 cells were inoculated by portal circulation injection, and
5

mice were provided BSO in drinking water. Metastatic colonization was
measured by liver mass after 28 days. Representative gross histology is
shown. n=8.
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2.7 Discussion

Glycolytic deregulation in cancer
Metabolic deregulation has recently emerged as a hallmark of
cancer (Cairns et al., 2011; Hanahan and Weinberg, 2011; Kaelin and
McKnight, 2013). Following Warburg’s observation of cancer cell
dependence on aerobic glycolysis (Warburg, 1956), molecular dissection of
glycolytic control has revealed the proliferative benefits of gene
expression changes under hypoxia as well as metabolite diversion
(DeBerardinis et al., 2008; Semenza, 2007; Vander Heiden et al., 2009). The
pyruvate kinase M2 isoform enzymatic catalysis is a key regulatory event
for glycolysis, controlling both glycolytic flux for energy demands and
flux towards biosynthetic pathways of nucleotides, amino acids, and
reducing power for cancer cell proliferation and antioxidant generation
(Anastasiou et al., 2011; Chaneton et al., 2012; Christofk et al., 2008a;
Christofk et al., 2008b). Cancer cells take advantage of this regulation—
PKM2 pyruvate kinase activity can be inhibited through destabilized
subunit interactions and resultant loss of homotetramer structure, which
is required for maximum enzymatic activity (Vander Heiden et al., 2009).
Our findings reveal that colon cancer cells utilize an additional means of
PKM2 regulation, namely expression of an additional isozyme PKL.
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Utilization of pathways endogenous to metastatic niche
The advantageous expression of liver-specific pyruvate kinase in
cancer cells to allow for metastatic growth in the liver suggests that
Paget’s ‘seed and soil’ hypothesis can be explained in part by cancer cell
utilization of pathways endogenous to cells at the metastatic niche (Fidler,
2003). The PKL isozyme is essential for hepatocytes as the sole enzyme for
glycolytic pyruvate production and regulated flux through alternative
pathways. This importance is highlighted by regulation of hepatic PKL
activity and expression in response to glucagon, insulin and dietary
carbohydrates (Yamada and Noguchi, 1999). Since hepatocytes experience
significant oxidative stress as a result of hypoxemic blood supply and
xenobiotic metabolism (Jungermann and Kietzmann, 1996), antioxidant
supply and controlled flux towards glutathione regeneration is likely
critical for hepatocyte survival and function. Future studies into the
regulatory role of PKL in hepatocytes will clarify this enzyme’s function in
normal physiology. While early metastatic colonization can be achieved
through utilization of organ-specific nutrients (Loo et al., 2015), cancer cell
activation of pathways endogenous to the metastatic niche appears to
contribute to continued progression of metastatic colonies.
Whereas the liver actively promotes high pentose phosphate
pathway activity in mammals (Cabezas et al., 1999), colon cancer cells
modulate glycolysis through expression of PKLR, consistent with the
enhancement of pentose phosphate pathway flux and regeneration of
glutathione required for survival in the liver. The importance of
glutathione levels is highlighted by further, independent promotion of
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glutathione levels: increased expression of GCLC, the rate-limiting
reaction in glutathione synthesis. While GCLC and PKLR function
appears to be critical regulatory steps that are broadly utilized by colon
cancer metastases as suggested by clinical expression association, other
mechanisms may be additionally utilized to ensure sustained glutathione
levels such as activation of hepatocyte glutathione efflux to allow for the
import of glutathione precursors from plasma (Obrador et al., 2011).
Nevertheless, glutathione levels appear critical for metastatic cell survival
and represent a potential clinical target.

Therapeutic potential of metabolic modulation
Therapeutic inhibition of glutathione synthesis can suppress liver
colonization through increasing cancer cell apoptosis, suggesting that
targeting this pathway has potential to induce cell death of alreadyformed metastatic nodules. BSO has been previously tested in a phase I
clinical trial on a variety of advanced cancers as an adjuvant and has
demonstrated both significant glutathione suppressive activity as well as
minimal toxicity (Bailey et al., 1997). Additionally, the development of
more potent inhibitors of GCLC may allow for enhanced efficacy
(Tokutake et al., 1998). Given that small-molecule activation of PKM2 is
being investigated as a strategy to suppress tumor growth (Anastasiou et
al., 2012), the findings presented here suggest that glycolytic activation
might display additional apoptotic effects in liver metastasis. The poor
survival of patients with metastatic disease and the need for therapies
specific to metastasis warrants further development of metabolic
modulation as a therapeutic approach.
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2.8 Materials and Methods

Cell culture
LS174T, LS-LVM3b, SW620, SW480, and WiDr cell lines were propagated
as previously described (Loo et al., 2015) and were obtained from ATCC
except for in vivo-selected LS-LVM3b derived in the laboratory. All cell
lines were labeled with luciferase reporter construct for in vivo
bioluminescent monitoring (Hickson et al., 2010). LS174T, LS-LVM3b, and
WiDr cell lines were maintained in DMEM media supplemented with 10%
FBS, glutamine, pyruvate, penicillin, streptomycin and Fungizone. SW620
and SW480 were maintained in McCoy’s media supplemented with 10%
FBS, glutamine, pyruvate, penicillin, streptomycin and Fungizone. The
cell lines used were selected to represent the mutational spectrum most
commonly seen in patients (Kras wild-type/mutant, Braf wildtype/mutant, MSS/MSI). Cells in culture were routinely tested for
mycoplasma contamination. Standard cell culture conditions for these cell
lines are considered to be cell seeding at a density of approximately 50-100
cells/mm , growth at 37°C and 5% CO , and dissociation and dilution of
2

2

cells before reaching confluency.

shRNA screening
10 subpools of lentiviral particles from the TRC1 human shRNA pooled
library (Sigma), consisting of 71,444 shRNA clones representing 14,523
genes, were transduced into luciferase-expressing LS174T, WiDr and
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SW620 colon cancer cell lines. Two transductions for each cell line were
performed as biological replicates at a low titer (MOI < 1) to reduce the
likelihood of multiple shRNAs in a single cell. Transductions were
performed with 8ug/ml of Polybrene (Millipore) to enhance efficiency. 48
hours after transductions, puromycin was added at a concentration of
2ug/ml until un-transfected cells died to select for cells with stable
integrants. After antibiotic selection, the remaining cells were allowed to
recover for a week prior to subsequent experiments. A portion of the
selected cells were set aside and genomic DNA extracted. This is the
reference pool of genomic DNA prior to the selective pressure of liver
colonization. A second population of the cells was used for in
vivo experiments, while a third was kept in culture for the duration of
the in vivo experiment. For direct liver injections, 800K cells from each
transduced population containing a single subpool was inoculated into an
average of 7 mice, summing to 204 mice in total for all subpools and cell
lines and allowing for a 783x depth of coverage. After 3 to 4 weeks when
tumors had developed as measured by bioluminescence (approximately
10 -10 photons/s), mice were sacrificed, and tumors were resected. Cells
9

10

from the various conditions were processed by isolation of genomic DNA
using DNeasy kit (Qiagen). A total of 5ug of genomic DNA isolated from
tumors from different mice were pooled and PCR amplification of shRNA
inserts was performed using 10 reaction tubes and pooled. A first
amplification

was

performed

using

touchdown

PCR

( Fwd_rd1:

TGGACTATCATATGCTTACCGTAACT;Rev_rd1:
AAAGAGGATCTCTGTCCCTGT. The PCR product from all 10 reactions
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(~350 bp) were gel-purified and pooled. Subsequently, a second round of
amplification was performed with Illumina-sequencing specific primers
(Fwd_rd2: AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTA
CACGACGCTCTTCCGATCTGTATTCTTGGCTTTATATATCTTGTGGA
AAGGAC,
Rev_rd2: CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTGGATG
AATACTGCCATTTGTCTCGAGGTCGA). The subsequent PCR product
was gel purified (~300bp) in preparation for high-throughput sequencing
on Illumina HiSeq2000. Once the sequencing results were obtained, the
data was filtered to normalize samples by total reads and to remove
shRNAs that were not included in all reference samples. 54,591 shRNA
clones representing 14,095 genes were used in the final data analysis. For
each sample, shRNA ratios to the reference cell line were calculated, and
z-scores were calculated using peak median absolute deviation (PMAD)
(Luo et al., 2008) to normalize for the global loss of shRNAs under these
experimental conditions. Given the effects of off-target RNAi silencing,
genes were scored as hits only if at least two shRNAs in each cell line were
absent from the final tumor samples in both independent transduction
replicates. The secondary library was generated by cloning a top-scoring
shRNA from the large-scale screen into plko.1 and producing a viral
library that was subjected to the experimental procedures listed above.
Gene scoring by RIGER algorithm was performed using weighted-sum
method on shRNAs in all cell lines. Gene ranking was averaged across cell
lines, which was then used to calculate gene percentile. To identify
kinases, genes from the top 556 hits were selected if annotated as a kinase
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by GO annotation KINASE_ACTIVITY (GO: 0016301) and mean depletion
in the secondary screen was greater than 2 z-scores. These kinases were
then assessed for their gene percentile score by RIGER.

Stable cell lines
Virus was generated using ViraSafe lentiviral packaging system (Cell
Biolabs). shRNA plasmids used were obtained from Sigma TRC library.
Indicated shRNAs (Sigma) are as follows: shControl (SHC002), PKLR sh83
(TRCN0000006383),

PKLR

sh84

(TRCN0000006384),

PKLR

sh39

(TRCN0000199139),

PKLR

sh40

(TRCN0000194740),

GCLC

sh64

(TRCN0000333564), and GCLC sh62 (TRCN0000344862). Because shRNAs
displayed varying efficacy depending on the cell line used, shRNAs used
for experiments were selected among multiple for the best-depleted
efficiency. To generate overexpression, N-terminal FLAG tag or HA tag
was added to cDNA of PKL/PKR or PKM2, respectively, and cloned into
pBabe-Puro or pBabe-Hygro expression vector. Transductions were
performed with 8ug/ml Polybrene (Millipore).

Animal studies
Animal experiments were conducted in accordance with protocols
approved by the Institutional Animal Care and Use Committee at The
Rockefeller University. NOD-SCID male mice, aged 6 weeks, were used in
experiments involving direct liver injections and LS-LVM3b cells. NODSCID gamma male mice, aged 6-8 weeks, were used in all other
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experiments. For direct liver injections, cells in PBS were mixed with
Matrigel (Corning) at a 1:1 ratio and injected with a total volume of 20ul
into the most anterior lobe. For subcutaneous injections, cells in PBS were
mixed with Matrigel (Corning) at a 1:1 ratio and injected with a total
volume of 100ul bilaterally near hind limbs. For portal circulation
injections, cells in PBS were injected into the spleen with the direction of
circulatory flow in a volume of 50ul. After 30 seconds to allow for
complete exit of cells from spleen, the spleen was removed by cautery. For
cecal injections, cells in PBS were mixed with Matrigel (Corning) at a 1:1
ratio and injected with a total volume of 20ul into the cecal wall. To
monitor tumor burden, mice were inoculated with 1.67mg D-luciferin
(Perkin Elmer) in 100ul by suborbital injection, and photon flux was
immediately

measured

in

IVIS

Lumina

System

(Perkin

Elmer).

Bioluminescence was performed immediately following cell inoculation
with an exposure time of 5 min and weekly thereafter unless otherwise
noted with an exposure time of 1 min. Tumor burden over time between
groups was performed by normalizing to matched bioluminescence signal
immediately following cell inoculation. To monitor apoptosis, mice were
inoculated with 0.83mg of Z-DEVD-aminoluciferin (VivoGlo Caspase 3/7
Substrate, Promega) in 100ul by suborbital injection, and photon flux was
immediately measured with an exposure time of 5 minutes in IVIS
Lumina System as a measure of early apoptotic cells. 3 hours later, total
tumor burden was measured using D-luciferin as described above.
Relative apoptotic cell burden at a given time point was calculated by
taking the ratio of bioluminescence signal obtained using Z-DEVD76

aminoluciferin over the bioluminescence signal obtained with D-luciferin.
To calculate an apoptosis rate, for each mouse, the relative apoptotic cell
burden was plotted over time, and the area-under-the-curve (AUC) was
calculated between t=0 and each time point. The calculated AUC data
points were plotted over time, and a linear regression was performed. For
N-acetyl cysteine treatments, mice were providing 40mM NAC drinking
water with the pH matched to control water and the solution replaced
twice weekly. BSO treatment studies were performed by supplying BSO
in drinking water at 20mM, a dose previously demonstrated to display no
significant toxicities in mice (Watanabe et al., 2003), and the solution was
replaced twice weekly. Mice were randomized following cancer cell
inoculation and prior to treatment.

Patient-derived primary colon cancer graft
CLR1 was derived from the liver metastasis of a subject with recurrent
rectal adenocarcinoma with a KRAS G12 mutation. Within two hours of
surgical resection, tumor tissue not needed for diagnostic purposes was
implanted subcutaneously into two NSG mice at the Antitumor
Assessment Core at Memorial Sloan-Kettering Cancer Center. When the
tumor reached 1,000 mm , mice were euthanized, tumor was excised, and
3

a 100 mm piece of tumor tissue was reimplanted into another set of mice
3

at

Rockefeller

University.

To

maintain

the

xenograft

line,

the

subcutaneous tumor was passaged each time the tumor reached 1,000
mm . The cells used for the splenic injection of CLR1 had been passaged
3
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subcutaneously six times prior. To obtain a single-cell suspension for
injection, mice were euthanized, and the subcutaneous tumor was excised
and subjected to a series of mechanical and enzymatic separations to
obtain a single-cell suspension. Cells of mouse origin were depleted from
the single-cell suspension via magnetic-activated cell sorting using the
mouse depletion kit (Miltenyi Biotec), leaving only cells derived from
human colorectal cancer.

Quantitative RT-PCR
RNA was extracted using total RNA isolation kit as indicated by
manufacturer (Norgen Biotek). cDNA was generated using Superscript III
(Invitrogen). Fast SYBR Green Master Mix (Life Technologies) was used to
analyze samples on Applied Biosystems 7900HT. Expression was
normalized to HPRT expression. Primers sequences are as follows: HPRTF:

GACCAGTCAACAGGGGACAT,

CCTGACCAAGGAAAGCAAAG,

HPRT-R:
PKLR-F:

TGGGAAAACTGGGTGGGATGGATG,
PKLR-R:

GAAGGAAGCAGCCGGGGATTTGAC,

GACCCATGGAGGTGCAATTA ,

GCLC-F:
GCLC-R:

AACCTTTGACAGTGGAATGAGA

Clinical analysis
The following datasets were used for analysis: GSE41258, GSE50760,
GSE6988, GSE14297, GSE18105, GSE27854, and GSE14095. RNA78

sequencing data was normalized to total reads per sample. Affymetrix
microarrays were analyzed for PKLR expression using probe 210451_at,
which displayed the highest counts.

Immunofluorescence of frozen sections
Livers were harvested from mice, washed with PBS, and fixed in 4%
paraformaldehyde overnight. The following day, livers were washed with
PBS, submerged in 30% sucrose until fully saturated, and then frozen in
OCT solution on dry ice and stored at -80 degrees Celsius. Frozen liver
blocks were sliced on tissue microtome in 10um sections and treated with
methanol:acetone on slides. Slides were stained with the following
antibodies: anti-Luciferase (1:100, Pierce), anti-cleaved Capase-3 (1:1000,
Cell Signaling), and anti-hVimentin (1:40, Vector laboratories). Fluorescent
secondary antibodies (1:250, Invitrogen) were applied for labeling of
primary antibodies. DAPI was added prior to mounting. Slides were
imaged on Leica TCS SP5 system.

Hypoxia and high cell density assay
Hypoxia was performed using 1% O 5% CO , 94% N mixed gas (Praxair)
2,

2

2

in a Modular Incubator Chamber (Billups-Rothernberg). High cell-density
was defined as a seeding density of 1000 cells/mm . Experiments were
2

performed in 6-well or 12-well plates using 2mL and 1mL of media,
respectively.
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Flow cytometry
All experiments were done after 24 hours under conditions of high celldensity and hypoxia. Apoptosis was assessed using GFP-certified
Apoptosis/Necrosis detection kit (Enzo Life Sciences). AnnexinV cells
+

were considered apoptotic, and AnnexinV , 7-AAD cells were considered
-

-

live. For rescue experiments, N-acetyl cysteine was pH adjusted to 7.4 and
used fresh at 2.5mM. GSH-MEE (Sigma) was used at 1mM. For
glutathione measurements, ThiolTracker Violet (Life Technologies) was
used according to manufacturer’s instructions at 10uM and analyzed in
combination with 7-AAD to exclude dead cells. Cells were analyzed on
LSRII (BD). Analysis was performed on FloJo. Experiments were
performed in biological triplicate and were repeated at least twice.

Co-immunoprecipitation & western blotting
Cells were lysed using 50mM Tris, pH 7.5, 150mM NaCl, 1mM EDTA, 1%
NP40,

protease

inhibitor

(Roche),

and

phosphoSTOP

(Roche).

Immunoprecipitation was performed using anti-FLAG M2 magnetic
beads (Sigma) or anti-HA magnetic beads (Pierce) for 1 hour at 4 degrees
Celsius. For FLAG-based immunoprecipitation, beads were washed 2x
with wash buffer containing 1M NaCl followed by a wash with wash
buffer containing 50mM NaCl. For HA-based immunoprecipitation, beads
were washed 2x with lysis buffer. Elution was performed using either 3x
FLAG peptide (Sigma) or HA peptide (Pierce). Samples were reduced
with reducing agent (Life Technologies), denatured, separated by SDS-
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PAGE, transferred to PVDF membrane (Pierce or Millipore), blocked with
5% milk or 5% BSA, and probed with primary antibody. The following
antibodies were used: anti-FLAG (1:1,000; Sigma), anti-PKM2 (1:1,000; Cell
Signaling), anti-PKLR (1:75; Santa Cruz), and anti-HA (1:1,000; Cell
Signaling). For PKM2 and HA detection, fluorescent secondary antibodies
(1:10,000; Li-Cor) were used and detected on Odyssey SA Imaging System
(Li-Cor).

For

PKLR

and

FLAG

detection,

antibodies

were

chemiluminescently detected using horseradish peroxidase–conjugated
secondary antibodies (1:10,000), ECL2 Western Blotting Substrate (Pierce)
and the SRX-101A (Konica Minolta) developer, according to the
manufacturer’s instructions.

Label Free Quantitation LC-MS/MS and analysis
Co-immunoprecipitated and 3xFLAG eluted proteins were trypsinized insolution overnight. Peptides were desalted using home-made Empore C18
columns prior to being analyzed by LC-MS/MS (Dionex 3000 HPLC
coupled to Orbitrap XL, Thermo Scientific). Peptides were separated at
300nL/min using a gradient increasing from 10% B to 45% B in 120
minutes (A: 0.1% Formic Acid, B: Acetonitrile/0.1% Formic Acid).
Generated LC-MS/MS data were queried against Uniprots complete
Human Proteome (August 2013) and quantitated using MaxQuant
1.5.0.30. In short, Peptide Spectrum Match false discovery rate was set to
1% while protein false discovery rate was set to 1%. A total of 1,140
proteins were matched. Match between runs were used for the label free
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quantitation. Generated label free quantitation values were analyzed
using Perseus 1.5.0.9. All LFQ values were log2 transformed and filtered,
requiring that a given protein displayed at least five matching peptides
and three times as many peptide spectrum matches (PSMs). This resulted
in 109 proteins. Absent LFQ values were replaced by a value one order of
magnitude less.

Pyruvate kinase assay
10 LS174T cells were seeded in triplicate in 6-well plates in 1% O for 16
6

2

hours. Immunoprecipitation was performed as described above for HAtagged proteins. Following elution of immunoprecipitated pyruvate
kinase complex, PK activity was measured using lactate dehydrogenase
(LDH)-coupled assay (Christofk et al., 2008b). Each reaction was
performed under the following conditions: 50mM Tris, pH 7.5, 100mM
KCl, 10mM MgCl2, 1mM PEP, 1mM ADP, 200uM NADH, 8 units LDH in
50%

glycerol,

and

100uM

FBP.

Activity

was

normalized

to

immunoprecipitated HA-tagged PKM2 levels as measured by Li-Cor
quantitative western blotting. Assay was monitored for pyruvatedependent conversion of NADH to NAD+ by fluorescence on Biotek
Synergy Neo. For whole cell lysates, pyruvate kinase activity assay
(Biovision) was used according to manufacturer’s instructions by
fluorescent measurements. Activity was normalized to relative live cell
proportion as measured by cell counting with trypan blue dead cell
exclusion.
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Pathway analysis
Gene Set Enrichment Analysis (Subramanian et al., 2005) was performed
on a list ranked by enrichment of proteins in FLAG-PKL/FLAG-PKR
immuno-precipitated samples using the most abundant proteins relative
to control based on the sum of peptide spectrum matches per protein.
Curated C2 gene sets from version 4.0 of the MSigDB were used for
analysis.

Pyurvate assay
3x10 cells were seeded in 60mm plate in triplicate and grown under 1% O
6

2

for 24 hours in recommended media without supplemental sodium
pyruvate. Cells were washed with PBS containing 100uM phloretin and
lysed and deproteinized using perchloric acid precipitation (Biovision).
Pyruvate and PEP assays (Biovision) were used by fluorometric methods
to quantify intracellular metabolite levels.

Recombinant protein production
PKL and PKR cDNAs were cloned into pGEX-6P-L vector, followed by
transformation in BL21 (DE3) Gold (Agilent). 0.1mM IPTG was used to
induce expression and after 3 hours, cells were lysed using 50mM TrisHCl, pH 7.5, 5mM EDTA, 200mM NaCl, 0.1% NP-40, 1mM DTT, 5mg/ml
lysozyme and sonicated (Misonix Sonicator S-4000). Purification was
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performed using glutathione-agarose beads (Sigma) and eluted using
5mM reduced glutathione (Sigma). Cleavage of GST-tag was performed
using Prescission protease (GE).

Additional in vitro cell growth assays
Anoxia was generated using the AnaeroPack System (Mitsubishi Gas
Chemical). Cell culture under acidic pH was obtained by using MES
buffer and adjusting to pH 6.6. Anchorage-independent growth was
performed as follows: cells were suspended in 0.4% agar in cell culture
media and layered on top of 0.6% agar in 24-well plates. Colonies formed
with feed media changed every 4 days and were counted and imaged by
light microscopy at 14 days. Invasion assays were performed by seeding
cells on top of Matrigel invasion chambers (BD) and using light
microscopy to image and quantify the number of cells that passed through
to bottom well.

Statistics
Bootstrapping was performed by sampling with replacement in R.
ANCOVA testing was performed using aov() command in R. Sample size
in mice experiments was chosen based on biological variability observed
with a given genotype. Non-parametric tests were used when normality
could not be assumed.
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CHAPTER 3: Highly Variable Cancer Subpopulations that Exhibit
Metastatic Fitness and Transcriptomic Variability
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3.1 Introduction

Non-genetic cell-to-cell variability in cancer
While the majority of intra-tumoral heterogeneity described to date
focuses on genetic diversity, the mechanisms that govern non-genetic
diversity remain poorly characterized.

Much of the challenge is due to

the inherent genetic instability of cancer populations. As an individual
tumor progresses over time, the genetic background changes with many
beneficial as well as neutral mutations incorporated into the population.
Additionally, the variation from patient-to-patient hampers clinical
analyses and makes controlling for mutational differences nearly
impossible.
However, there exist precedence for non-genetic mechanisms to
contribute

to

cancer

progression

and

metastatic

growth.

While

chemotherapy resistance has been well-characterized to be mediated by
genetic mutations in a number of cases (Gerlinger and Swanton, 2010),
colorectal cancer clonal populations can display significant variability in
the ability to form tumors and respond to chemotherapy despite stable
genetic lineages over time (Kreso et al., 2013), suggesting non-genetic
mechanisms as the source of molecular variability generation (Singer et
al.,

2014).

Other

studies

have

observed

non-genetic

cell-to-cell

heterogeneity that enhances fitness of cells under cytotoxic conditions
with chemotherapies (Gupta et al., 2011; Kreso et al., 2013; Sharma et al.,
2010; Spencer et al., 2009). Furthermore, molecular variability in the
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dynamic response to chemotherapies can influence survival of cancer
populations (Cohen et al., 2008).
It remains unclear whether non-genetic phenotypic diversity in
cancer is molecularly regulated or whether it is simply biological noise
(Marusyk and Polyak, 2010). Stochastic noise may be derived from
inherently noisy processes such as transcription and translation (Brock et
al., 2009). On the other hand, population heterogeneity in tumors can be
driven by specific molecules that mediate subclonal interactions,
balancing cell proliferation and cell competition (Marusyk et al., 2014).
Further characterization of the mechanisms that govern phenotypic
diversity will enable distinction between stochastic and deterministic
noise. Nevertheless, non-genetic heterogeneity is an inherent yet currently
poorly understood aspect in cancer that has the potential to enhance
Darwinian evolution through increasing variability of a beneficial trait
(Brock et al., 2009).
The clinical presentation of metastases suggests that metastatic
progression may be driven in part by non-genetic mechanisms. The
mutational status of metastatic tumor nodules fails to lend credence to
genetic instability as the source of molecular diversity. Metastatic tumor
nodules from breast, colorectal, and pancreatic cancers display a limited
number of mutations, and of those found, none have been causally linked
to the development of metastases (Ding et al., 2010; Jones et al., 2008;
Yachida et al., 2010). Additionally, the amount of time needed to develop
metastasis can be rapid, being as little as a year in the twenty-year lifespan
of colorectal cancer (Jones et al., 2008). With multiple, independent, highly
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selective steps in the metastatic cascade, it is unclear how a sufficient
number of cancer-promoting mutations, which so far have not been
detected by sequencing analyses, could contribute to this rapid cancer
evolution.

Clonal heterogeneity as a model for non-genetic variation
The study of non-genetic variability was pioneered in bacterial
systems because of the genetic homogeneity of strains. In 1976, Koshland
demonstrated that individual E. coli cells displayed variable phenotypic
responses to stimuli despite being genetically identical (Spudich and
Koshland, 1976). Furthermore, clonal populations of E. coli allowed for
quantification of biological noise at the molecular level in genetic lineages
(Elowitz et al., 2002; Taniguchi et al., 2010). To study non-genetic
variability in clonal cancer populations, genetic variation must be
accounted for. This can be accomplished in part by limiting the number of
cells divisions, thus reducing the potential contribution of functional
genetic mutations to the population. Additionally, genomic analyses of
cancer populations following clonal expansion would allow for an
assessment of genomic integrity. This approach has been performed to
characterize phenotypic variability of clonal colorectal cancer populations
to form tumors and respond to chemotherapy (Kreso et al., 2013).
Utilization of clonal analyses in cancer populations can allow for better
understanding of the non-genetic variability that may be contributing to
metastatic colonization.
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3.2 Isolation of clonal subpopulations with enhanced diversification capacity

Morphologic diversification
To generate an experimental model wherein genetic variation
between cells is minimized so that non-genetic contributions to
heterogeneity generation can be assessed, clonal subpopulations were
derived from human cancer populations. The breast cancer cell lines
MDA-MB-231 (MDA) and the minimally passaged CN34 breast cancer
line (CN), both originally derived from the pleural effusion of patients
with metastatic breast cancer (Bos et al., 2009; Cailleau et al., 1978) were
seeded sparsely to allow individual cells to proliferate into isolated
colonies. Once colonies could be visualized, these subpopulations were
grown individually until cells could be seeded for microscopy. Nearly two
hundred clonal subpopulations from these two cell lines were isolated.
Next, each subpopulation was assessed by microscopy to
determine whether clonal populations could generate morphological
variability following clonal expansion. Microscopic imaging was
performed on cell populations labeled with CellMask stain to label entire
cells and DAPI dye to label nuclei, and images were analyzed by
automated image analysis to measure size parameters of individual cells,
which include cell area, cytoplasmic area, nucleus size, perimeter, major
axis length, and minor axis length. When cell size parameters were
compared between subpopulations, there was significant inter-clonal
variation (Figure 3.1). Namely, certain subpopulations consisted of large
cells, while others consisted of primarily small cells.
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Figure 3.1: Clonal subpopulations display inter-clonal variation
Size parameters were measured for clonal subpopulations generated from
MDA-MB-231 (a; n=98) and CN34 (b; n=97) breast cancer cell lines.
Median, interquartile range, minimum, and maximum are depicted by
box plots. Representative populations of small-sized and large-sized cell
populations are shown; scale bars are 50um. CellMask red was used to
label entire cells, while DAPI dye was used to label nuclei.
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To identify subpopulations that generate morphological variability,
the distribution of cell size within a population was assessed by
calculating the coefficient of variation for each size parameter.
Furthermore, principal component analysis on the six coefficient of
variation measurements was performed to generate a single linear
measurement

of

intra-clonal

variability.

The

majority

of

clonal

subpopulations displayed a range of variability as assessed by using the
first principal component—consistent with a single peak distribution
(Figure 3.2). Notably, a few subpopulations demonstrated exceptionally
high intra-clonal cell size variability without exhibiting significant
differences in their population-level means (Figures 3.2, 3.3). These
subpopulations served as candidates that have the capacity to generate
phenotypic diversity.
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Figure 3.2: Identification of subpopulations with high intra-clonal
variation
Histograms of the first principal component of size coefficient of variation
(CV) was used to assess subpopulation size variability of MDA-MB-231derived clones (a) and CN34-derived clones (b). Candidate high
variability populations are indicated in red. Representative images of high
and low variability subpopulations are shown on the right. Scale bars =
50um.
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Figure 3.3: Variability in cell area in candidate high and low variability
populations
Distribution of cell area as shown from candidate high and low variability
populations in MDA-MB-231-derived clones (a) and CN34-derived clones
(b). Median, interquartile range, minimum, and maximum are depicted by
violin plots.
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Phenotypic diversification
To determine if these subpopulations could give rise to and
maintain phenotypic diversity beyond cell size, proliferative variability
was assessed as an independent functional measure by colony formation
assays. Cells from each subpopulation were seeded sparsely, allowed to
grow into colonies, and then were stained with crystal violet to allow for
macroscopic measurements. A macroscopically small colony would be
indicative of a slower colony growth rate, whereas a large colony would
indicate a faster colony growth rate. Thus, proliferative variability would
manifest as both small and large colonies derived from the same
subpopulation. Cell size and cell density within colonies were first
assessed to confirm that these factors were not contributing to colony area
differences (Figure 3.4).
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Figure 3.4: Cell size and cell density are not responsible for colony area
differences
Representative images of cells in a colony from colony formation assay are
shown; scale bar is 100um.

While bulk population growth in culture was observed to be
similar

between

subpopulations

(Figure

3.5),

MDA-derived

subpopulations that exhibited high intra-clonal size variability also
displayed high variability in proliferative capacity, which could be
visualized as high variability in colony sizes (Figure 3.6a). Among the CNderived populations, only subpopulation C57 displayed a modest increase
in proliferative variability (Figure 3.6b), suggesting that the other
morphologically variable subpopulations from this parental line may not
exhibit variation of additional phenotypes beyond morphology.
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Figure 3.5: Population growth in culture is not different between high
and low variability subpopulations
5x10 cells were seeded and assessed 72 hours later for viable cells using
3

WST-1 reagent for MDA-MB-231-derived subpopulations (a) and CN34derived subpopulations (b). P-values were derived from two-sided
student’s t-test (two-sample for MDA, one-sample for CN).
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Figure 3.6: High variability subpopulations exhibit proliferative
variability
MDA-MB-231-derived colonies (a) and CN34-derived colonies (b) were
grown in triplicate plates and measured for variability in colony area.
Error bars indicate s.e.m. of three independent experiments. P-values were
generated by testing Pearson’s correlation coefficient with two-sides.
Representative images of colonies stained by with crystal violet and
thresholded in ImageJ are shown on right; scale bar is 5mm.
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These subpopulations, herein referred to as high variability
subpopulations, were next assessed for whether the observed variability
was

heritable.

High

variability

(HV)

and

low

variability

(LV)

subpopulations were seeded sparsely to allow for isolation of clonal
progeny. These clonal progeny were expanded to allow for microscopic
imaging of population cell sizes. High variability subpopulations
maintained high cell size variability in progeny clonal subpopulations as
compared to low variability subpopulations (Figure 3.7).

Figure 3.7: Progeny from high variability subpopulations maintain size
variability after clonal isolation and expansion
Single cells isolated from indicated MDA-MB-231-derived (a) and CN34derived (b) subpopulations were expanded into clonal populations and
were assessed for cell size variability. P-values were derived using twosided Mann Whitney U test.
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To further characterize cell size variability, a number of additional
features were assessed. First, since size variability measured in twodimensions on cell culture plates could be due to either morphological
shape or cell volume, high variability subpopulations were assessed for
size variability in three-dimensions using ImageStream flow cytometry
with high content image analysis. Indeed, high variability subpopulations
exhibited size variability in three-dimensions (Figure 3.8), indicating
variation in cell mass. Next, it is possible that cell size variability could be
also attributed to altered cell cycle phasing as cells must grow in size prior
to mitosis. Cell cycle phasing as measured by flow cytometric analysis of
DNA content revealed no difference between high and low variability
subpopulations (Figure 3.9). Finally, cell size variability was assessed for
its robustness following passage in culture and growth at varying
densities. Increased cell size variability of high variability subpopulations
was maintained after passage in culture and regardless of seeding density
(Figures 3.10, 3.11). Taken together, these high variability clonal
subpopulations display an enhanced and heritable ability to generate
diversity across multiple phenotypic dimensions.
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Figure 3.8: High variability subpopulations exhibit three-dimensional
size variability
The first principal component of 3D size coefficient of variation was used
to assess three-dimensional size variability from indicated MDA-MB-231derived (a) and CN34-derived (b) subpopulations. Error bars indicate
s.e.m. of three independent experiments. P-values were derived using
two-sided t-test.
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Figure 3.9: High variability subpopulations exhibit no significant
difference in cell cycle phasing
Fixed cells from indicated MDA-MB-231-derived (a) and CN34-derived
(b) subpopulations were stained with DAPI and analyzed by flow
cytometry to measure DNA content. Histograms of each population are
shown (left). Watson pragmatic cell cycle analysis was performed in
FlowJo to assess cell cycle phasing (right).
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Figure 3.10: High variability subpopulations maintain relative size
variability after passage in culture
Subpopulations from indicated MDA-MB-231-derived (a) and CN34derived (b) subpopulations were passaged five times in culture under
standard cell culture conditions and then imaged and analyzed for cell
size coefficient of variation.
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Figure 3.11: High variability subpopulations exhibit increased cell size
variability at different seeding densities
Indicated MDA-MB-231-derived (a) and CN34-derived (b) subpopulations
were seeded at various densities and then imaged and analyzed for cell
size coefficient of variation.
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3.3 High variability subpopulations exhibit metastatic fitness

Systemic metastasis
Metastatic colonization of an end organ represents a major
bottleneck during cancer evolution that would greatly benefit from
diversity generation and is clinically responsible for the majority of cancer
deaths (Aktipis et al., 2013; Gupta and Massague, 2006; Klein, 2013). The
identification of subpopulations with high versus low diversification
potential from the same individual patients’ cancer populations allowed
for testing the impact of intra-clonal diversification capacity on metastatic
colonization. Because diversity generation should broadly enhance cancer
evolution, in the context of the metastasis, diversity is likely to benefit
colonization of multiple organs by increasing the likelihood of successful
metastasis. To assess broad colonization capacity, cells were inoculated
into arterial circulation of mice by intracardiac injection, which allows
cells to arrest in the capillary beds of numerous organs. High variability
subpopulations exhibited enhanced systemic metastatic capacity as
determined by total tumor burden (Figure 3.12).

Additionally, this

increased tumor burden was in large part attributed to an increased
number of systemic metastatic foci (Figure 3.13), indicating an increased
frequency to colonize systemic sites as opposed to an increased growth
rate of the formed metastases.
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Figure 3.12: High variability subpopulations exhibit enhanced systemic
metastatic capacity
Bioluminescence quantification of total body metastatic burden by 4x10

4

MDA-derived cell populations after 42 days (a) and 2x10 CN-derived cell
5

populations after 72 days (b) following inoculation into arterial circulation
via intracardiac injection. P-values were derived using two-sample (a) and
one-sample (b) one-sided t-test; n=5-6. Representative mouse and organ
bioluminescence are shown.

105

Figure 3.13: High variability subpopulations exhibit increased systemic
colonization frequency
Systemic metastatic foci per mice were counted as distinct, minimal
bioluminescence signals cells from indicated MDA-MB-231-derived (a)
and CN34-derived (b) subpopulations. P-values were derived using twosample (a) and one-sample (b) one-sided t-test.

106

Organ metastasis
To confirm the increased colonization capacity of high variability
subpopulations in a more clinically relevant context, these populations
were assessed for the capacity to colonize the lung and liver, two of the
most common sites of breast cancer metastasis (Siegel et al., 2015). High
variability subpopulations derived from both human lines more efficiently
colonized the lung upon tail vein injection (Figure 3.14) and the liver upon
portal circulation injection (Figure 3.15), indicating that the enhanced
metastatic capacity is broadly applicable to multiple organs posing
diverse selective barriers. Additionally, to confirm that high variability
populations contribute to metastasis to a greater degree in a mixed
population with numerous subclones, a mixed population consisting of an
equal number of high and low variability cells labeled with barcodes was
generated. Portal circulation inoculation of this mixed population
revealed high variability cells to contribute between 81.2% to 99.6% of
formed liver metastases as measured by quantitative PCR of DNA
barcodes (Figure 3.16), demonstrating that high variability cells
maintained an increased metastatic capacity in a mixed population. The
ability of high variability subpopulations to both generate phenotypic
diversity and metastasize more efficiently is consistent with a positive role
for phenotypic diversification in cancer progression.
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Figure 3.14: High variability subpopulations exhibit increased lung
colonization capacity
Bioluminescence quantification of lung metastases by 4x10 MDA-derived
4

cell populations after 70 days (a) and 2x10 CN-derived cell populations
5

after 112 days (b) following inoculation into the tail vein. P-values were
derived using one-sided Mann Whitney U test; n=5. Representative
bioluminescence and lung histology is shown.
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Figure 3.15: High variability subpopulations exhibit increased liver
colonization capacity
Ex vivo bioluminescence quantification of liver metastases by 4x10 MDA4

derived cell populations after 39 days (a) and 2x10 CN-derived cell
5

populations after 91 days (b) following inoculation into the portal
circulation. P-values were derived using one-sided Mann Whitney U test;
n= 5. Representative bioluminescence and gross histology are shown.
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Figure 3.16: High variability subpopulations exhibit increased liver
colonization capacity in a mixed population
5x10 cells consisting of equal parts of HV-M42 cells, labeled with
5

blasticidin resistance gene, and LV-M100 cells, labeled with puromycin
resistance gene, were inoculated into the portal circulation. Liver
metastases were extracted after 28 days and processed for quantitative
PCR measurement of genomic DNA resistance genes.
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Clinical metastasis
In order to corroborate the role of phenotypic diversification in
metastatic progression, the next goal was to determine whether
phenotypic diversity was associated with clinical outcomes. Given the
observation of increased nuclear size variability in high variability
subpopulations (Figure 3.17) as well as the ability to distinctly label nuclei
with DNA stains, this tractably quantifiable parameter of nuclear size was
used as a readout of phenotypic variability in human invasive breast
cancer tumor core biopsies. A tissue microarray containing 168 useable
core biopsies of primary breast cancer tumors was stained with DAPI to
label nuclei, imaged by confocal microscopy, and analyzed by automated
image analysis to measure cancer cell nuclei sizes within each core.
Consistent with the findings in the clonal populations, nuclear area
variability of cancer cells was significantly increased in tumors of patients
with more advanced stage disease (Figure 3.18). Primary tumors that
progressed to lymph nodes displayed significantly higher variation in
nuclear area than lymph node negative tumors. Furthermore, primary
tumors that progressed to distant metastases exhibited significantly higher
nuclear area variation than those tumors that did not metastasize. Mean
nuclear size and mitotic index did not significantly correlate with disease
stage (Figure 3.19). These clinical correlations are consistent with our
findings that cancer populations with greater diversification potential
positively contribute to metastatic disease.
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Figure 3.17: High variability subpopulations exhibit increased nuclear
area variability
Nuclear area variability as measured by automated image analysis of
indicated

MDA-MB-231-derived

subpopulations.
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(a)

and

CN34-derived

(b)

Figure 3.18: Nuclear area variability associates with human breast cancer
metastasis
(a) NCI CDP Breast Cancer Progression Tissue Microarray was stained
with DAPI, imaged by confocal microscopy, and analyzed for nuclear area
coefficient of variation for each breast cancer core. P-values were derived
using one-sided t-test. (b) Representative images with measured cancer
cell nuclei (yellow boundary) are shown; scale bar = 50um.
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Figure 3.19: Nuclear area variability in human breast cancer is not
dependent on mean nuclear area or mitotic index
NCI CDP Breast Cancer Progression Tissue Microarray was stained with
DAPI, imaged by confocal microscopy, and analyzed for mean nuclear
area (a) and mitotic index (b) in each breast cancer core. P-values were
derived using one-sided t-test.
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3.4 Molecular characterization of high variability subpopulations

Genomic analysis
These clonal subpopulations of cells derived from isogenic
backgrounds offered the potential for studies into the molecular basis of
cancer variability. Given the contribution of genomic instability to tumor
heterogeneity (de Bruin et al., 2014; Greaves and Maley, 2012), high
variability subpopulations were assessed for mutational burden. Genomic
DNA was isolated from subpopulations and processed for whole exome
sequencing to allow for quantification of single-nucleotide variant and
insertion-deletion mutation frequencies. The mutational profiles allowed
for reconstruction of phylogenic relationships as subpopulations diverged
from an ancestral parent population (Gerlinger et al., 2012). Exome
sequencing revealed that high variability subpopulations diverged from a
common high variability ancestor and exhibited genetic similarity to the
parental

MDA-MB-231

population

(Figure

3.20),

indicating

that

substantial genetic mutational changes did not accumulate as these
subpopulations

clonally

expanded.

Furthermore,

high

variability

subpopulations did not differ in the number of population-specific nucleic
acid variants relative to low variability subpopulations or the parental
population (Figure 3.20). While it is difficult to exclude the contribution of
nucleic acid mutations to subpopulation heterogeneity, the comparable
genetic phenotypes and relative genetic stability in the isogenic high
variability subpopulations suggests that enhanced genetic diversification
may not be the primary source of the observed phenotypic diversity.
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Figure 3.20: No evidence of genomic instability as a factor associated
with high variability subpopulations
(a) Phylogenic tree based on genomic variant allele frequencies as
measured by exome sequencing from cell populations. Genetic distance of
subpopulations relative to MDA-MB-231 parent cell line (b) or from
inferred HV or LV common ancestor (c) as determined by Nei’s genetic
distance. (d) Variants found only in the indicated subpopulations at any
frequency greater than zero were counted.
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Transcriptomic variability
In order to identify additional molecular mechanisms that could
contribute to phenotypic diversity, single-cell RNA-sequencing from high
and low variability subpopulations was performed to assess gene
expression variability between cells (Figure 3.21), which could contribute
to

the

functional

variability

between

cells

in

high

variability

subpopulations. Cells were sorted by flow cytometry into individual wells
with lysis buffer to expose RNA for immediate generation of barcoded
cDNA. Barcoded cDNA was then pooled and processed for generation of
sequencing libraries.

Figure 3.21: Single-cell RNA-sequencing to compare cell-to-cell gene
expression variability
Schematic for single-cell RNA sequencing and transcriptomic variability
analysis.
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Assessment of single-cell RNA sequencing quality and fidelity
demonstrated appropriate spike-in expression and no difference in spikein variability between wells (Figure 3.22). Total transcript abundance per
cell showed no significant differences between high and low variability
subpopulations

(Figure

3.23).

Moreover,

global

mean

transcript

abundance was also not significantly different between high and low
variability subpopulations (P = 0.91 for HV-C57 vs LV-C92 & P = 0.62 for
HV-M42 vs LV-M26 by two-sided paired t-tests).

Figure 3.22: Spike-in expression and variability in single cell wells
indicates appropriate single-cell sequencing fidelity
(a) Mean expression of spike-in transcripts per well as assessed by single
cell sequencing was plotted against known spike-in concentrations. (b)
Coefficient of variation of spike-in transcripts between wells containing
the indicated population of cells was calculated. P-values were derived
using two-sided paired t-test.
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Figure 3.23: Single-cell total transcripts was similar between high and
low variability cells
Relative transcript abundance per cell from indicated MDA-derived
subpopulations (a) and CN-derived subpopulations (b).
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Interestingly, linear and nonlinear clustering (Amir el et al., 2013)
of single-cell transcript expression profiles could not classify high or low
variability subpopulations (Fig. 3.24), suggesting that averaged overexpression or repression of a gene or gene set may not be the primary
cause of phenotypic variation recurrently observed in high variability
subpopulations (Altschuler and Wu, 2010). However, global cell-to-cell
transcript expression variability, as assessed by quantification of 8,218
transcripts from single MDA-MB-231-derived high variability cells, was
significantly elevated relative to expression variability between single low
variability cells (53.9% transcripts with higher CV in HV-M42; P = 7e-8 by
two-sided paired t-test; Figure 2.25). The same was observed for single
cells from the HV-C57 subpopulation (5,826 transcripts; 55.0% transcripts
with higher CV in HV-C57; P = 3e-10 by two-sided paired t-test; Figure
3.25).
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Figure 3.24: Gene expression profiles of cells from high and low
variability subpopulations are similar
(a) Principal component analysis was performed on single-cell transcript
expression profiles from MDA-derived subpopulations (left) and CNderived subpopulations (right). (b) Visualization of transcript expression
profiles of 10 cells from selected MDA-derived subpopulations (left) and
12 cells from selected CN-derived subpopulations using t-distributed
stochastic neighbor embedding (t-SNE).
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Figure 3.25: High variability populations exhibit increased cell-to-cell
transcript expression variability
Transcriptomic variability analysis was performed by calculating
expression coefficient of variation for each transcript between cells from
MDA-derived subpopulations (a; n=10 single cells per population) and
from CN-derived subpopulations (b; n=12 single cells per population).
Mean transcript coefficient of variation was calculated for all transcripts.
P-value was derived from two-sided paired t-test. Percentages of
transcripts with higher CV in each population are shown. Representative
high variability transcripts in single cells are shown (right); n=10 single
cells for MDA-derived populations and n=12 single cells for CN-derived
populations.
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Characterization of transcriptomic variability
To assess the robustness of this molecular phenotype, sampling
analyses of the single-cell sequencing experiments were performed. While
more abundant transcripts are known to be detected with higher accuracy,
elevated transcriptomic variability was observed regardless of transcript
abundance (Figure 3.26). To determine whether sequencing from limited
number of cells affected the outcome, random sampling of single cells
from subpopulations was performed to determine if the enhanced
transcriptomic variability could be detected with fewer cells. Indeed,
transcriptomic variability was observed when setting the analysis to as
few as five cells per population (Figure 3.27). Additionally, to determine if
a unique cell was responsible for the molecular variability, sampling was
performed to assess population transcriptomic variability following
removal of each single high variability cell sequenced. Transcriptomic
variability was consistently detected regardless of which high variability
cell was excluded from the analysis (Figure 3.28), indicative of robust and
indiscriminate

population-level

variability.

While

the

increased

transcriptomic variability appears modest, this effect is consistently
observed under different analysis parameters and in two subpopulations
derived from independent breast cancer populations. Taken together,
these findings indicate that phenotypically diverse, metastatic cancer
subpopulations maintain enhanced intra-clonal transcriptomic variability
generation capacity.
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Figure 3.26: Increased cell-to-cell transcript expression variability is not
dependent on transcript abundance
Log-ratios of transcript CV mean were calculated by using varying
number of transcripts, ordered by descending mean single cell expression.
Analysis was performed using a minimum of 100 transcripts. All cells, 10
for each MDA-derived HV and LV subpopulation (a) and 12 for each CNderived HV and LV subpopulation (b), were used for analysis.
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Figure 3.27: Increased cell-to-cell transcript expression variability is
detected with as few as five cells per population
Log-ratios of transcript CV mean were calculated by sampling MDAderived (a) and CN-derived (b) HV or LV subpopulations 10 times using
different set sizes and calculating the mean transcript CV for HV and LV
subpopulations. P-values were derived using one-sided paired t-test. All
transcripts were used for analysis. Significant p-values are in red. Color
scales are shown.
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Figure 3.28: Increased cell-to-cell transcript expression variability is
detected regardless of which cell is excluded from analysis
Cumulative frequency distribution is shown from sampling analysis. (a)
All possible combinations of six cells were sampled from the 10 MDAderived HV cells with one specific cell removed (set size of 9) and
distribution of mean CV is plotted (blue, 10 possible combinations to
exclude each of the 10 cells). (b) All possible combinations of six cells were
sampled from the 12 CN-derived HV cells with one specific cell removed
(set size of 11) and distribution of mean CV is plotted (blue, 12 possible
combinations to exclude each of the 12 cells). Distributions of mean CV
from samplings of six cells from all HV cells (red, 1 possible combination
to include all cells) and all LV cells (grey, 1 possible combination to
include all cells) are shown.
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Transmission of variability to protein expression
To validate the relevance of transcriptomic variability as it pertains
to biological function, flow cytometry was used to assess protein-level
variation. XPNPEP3 and UPF2, two genes that displayed high transcriptlevel variability in both high variability subpopulations (Table 3.1) and
whose protein expression per cell could be readily quantified in a highthroughput manner by flow cytometry, demonstrated a consistent level of
increased protein expression variability in high variability subpopulations
(Figure 3.29). These findings were extended to the following additional
five proteins that could be readily quantified by flow cytometry: ALDOA,
PABPC1, HNRNPA1, CD110, and HNRNPA0. In all high and low
variability subpopulations, we observed a significant correlation between
transcript-level variation and protein-level variation for the seven genes
tested (Figure 3.30) with no consistent correlation in mean protein
abundance (Figure 3.31). These findings reveal that transcript variation is
transmitted to the protein level and highlight molecular variability as a
principal feature of high variability subpopulations.
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Table 3.1: Top 20 most variable genes in common to MDA-derived and
CN-derived high variability subpopulations
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Figure 3.29: Cell-to-cell transcript expression variability is transmitted to
the protein-level
Flow cytometry was used to assess UPF2 (a) and XPNPEP3 (b) protein
coefficient of variation in subpopulations by assaying over 2.5x10 cells. P4

values were derived using two-sample (MDA) or one-sample (CN) onesided t-test.
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Figure 3.30: Cell-to-cell transcript expression variability is correlated
with protein expression variability
Protein CV log-ratios of seven proteins as measured by flow cytometry
from MDA-derived (a) and CN-derived (b) subpopulations was compared
to transcript CV log-ratios measured by single-cell RNA sequencing. Pvalue was derived from testing Pearson’s correlation coefficient with oneside.
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Figure 3.31: Mean transcript expression is not consistently correlated
with mean protein expression
Protein mean expression log-ratios as measured by flow cytometry from
MDA-derived (a) or CN-derived (b) was compared to transcript mean
expression log-ratios as measured by single cell RNA sequencing.
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3.5 Spliceosome-related gene transcripts are high variability

Validation of spliceosome-related gene variability
The next goal was to identify a potential mechanism that could
contribute to transcriptomic variation in high variability subpopulations.
MDA-derived and CN-derived subpopulations displayed similarity in
high variability genes (Table 2.1), many of which alone could contribute to
global transcriptomic variability such as chromatin modifiers (SENP7,
ARID1A), transcription factors (TCF7L2, SP3), and regulators of nonsensemediated decay (UPF2). While individual genes are likely to contribute to
the effect seen in high variability populations, any coordinated variation
of a common subset of transcripts may reveal a major contribution to cellto-cell variability. To identify regulatory networks that might be
responsible for transcriptomic variation, variable transcripts were
searched for functional gene sets that might contribute to molecular
variability. Transcripts were binned into four categories depending on
whether relative transcript variability was increased in either or both
MDA-derived and CN-derived high variability subpopulations. Pathway
discovery analysis using iPAGE (Goodarzi et al., 2009) revealed
spliceosome machinery and myeloid cell differentiation gene transcripts
as the only two gene sets to exhibit higher expression variability in high
variability subpopulations derived from both patients’ cancer populations
(Figure 3.32). This raised the possibility that cell-to-cell variation in the
expression levels of splicing genes and the resultant mRNA processing
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activity may represent a conceivable mechanism through which
population-level heterogeneity of mature transcripts may be achieved at a
global scale (Munsky et al., 2012).

Figure 3.32: Pathway analysis reveals spliceosome machinery and
myeloid cell differentiation gene transcripts as gene sets with variable
expression
Pathway analysis was used to identify gene sets that are enriched in
transcripts with high expression variability in either or both HV
subpopulations. Enrichment scale is shown below.
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Intron retention variability
Intron retention, a product of improper splicing, is known to lead
to transcript degradation via non-sense mediated decay (Wong et al.,
2013). Increased intron retention could thus reduce the expression of a
large number of mature transcripts. Given the expression variation of
spliceosome machinery components, variation in constitutive spliceosome
activity in HV cells could cause enhanced variation in global intron
retention. Variation in intron retention could then contribute to transcript
abundance

variation.

Indeed,

high

variability

subpopulations

demonstrated higher cell-to-cell intron retention variation, as determined
by analysis of 1,132 matched introns from MDA-derived cells (54.8%
retained introns with higher CV in HV-M42, P = 1e-4 by one-sided paired
t-test; Figure 2.33) and 1,666 matched introns from CN-derived cells
(57.6% retained introns with higher CV in HV-C57, P = 2e-11 by one-sided
paired t-test; Figure 3.33).
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Figure 3.33: Intron retention variability is observed in high variability
subpopulations
Intron retention (IR) variability analysis was performed by calculating
expression coefficient of variation for each IR measurement between cells
from MDA-derived (a) and CN-derived (b) subpopulations. Mean IR
coefficient of variation was calculated. P-value was derived from onesided paired t-test. Percentages of retained introns with higher CV in each
population are shown. Representative high variability retained intron
expression in single cells is shown (right); n=10 single cells for MDAderived populations and n=12 single cells for CN-derived populations.
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Exon-exon junction variability
Additionally, if this intron retention variation is propagated,
variation should be apparent in further processed forms of pre-mRNA.
Indeed, exon-exon junction expression variability measured from single
cell sequencing experiments was significantly increased in high variability
subpopulations from MDA-derived cells (54.7% exon-exon junctions with
higher CV in HV-M42, P = 2e-4 by one-sided paired t-test; Figure 3.34)
and CN-derived cells (65.3% exon-exon junctions with higher CV in HVC57, P = 8e-10 by one-sided paired t-test; Figure 3.34). This molecular
variability could be caused by variation in splicing as well as varied decay
of improperly spliced transcripts. Consistent with our findings, intron
retention has been previously observed to be the most significant splicing
alteration in breast cancer patient samples (Eswaran et al., 2013). These
findings reveal enhanced splicing and intron-retention variability as one
feature of high variability subpopulations.
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Figure 3.34: Exon-exon junction variability is observed in high
variability subpopulations
Exon-exon junction transcript variability analysis was performed by
calculating expression coefficient of variation for each exon-exon junction
transcript between cells from MDA-derived (a) and CN-derived (b)
subpopulations. Mean exon-exon junction transcript coefficient of
variation was calculated. P-value was derived from one-sided paired ttest. Percentages of exon-exon junction transcripts with higher CV in each
population are shown. Representative high variability exon-exon junction
transcript expression in single cells is shown (right); n=10 single cells for
MDA-derived populations and n=12 single cells for CN-derived
populations.
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3.6 Variable cell-to-cell expression of SNRNP40 increases metastatic colonization

Engineered variation of SNRNP40 increases metastatic colonization
To determine if spliceosomal gene variability contributed to
increased metastatic colonization, the next goal was to assess whether
enforced modulation of a high variability spliceosomal gene could
recapitulate

the

metastatic

capacity

seen

in

high

variability

subpopulations. While high variability subpopulations display variability
in many spliceosomal genes, focused study on a single spliceosomal gene
could serve as a model by which other spliceosomal genes function, but
may recapitulate only a fraction of the effects seen in high variability
subpopulations. Focused study was performed on SNRNP40, a
component of the U5 snRNP complex, because this gene exhibited high
transcript variability in high variability subpopulations from single-cell
sequencing experiments (Figure 3.35), was among the top 3 most variable
spliceosomal gene transcripts from single-cell sequencing experiments
(Table 3.2), and whose protein expression could be readily quantified by
immunofluorescence-based imaging on confocal microscopy. Indeed, high
variability subpopulations displayed increased protein-level variability of
SNRNP40 (Figure 3.36).
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Figure 3.35: SNRNP40 transcript (NM_004814) is variable in high
variability subpopulations
Single cell expression of SNRNP40 transcript (NM_004814) from MDAderived (a) and CN-derived (b) subpopulations. P-value to test variation
was performed using Levene’s test.

Table 3.2: Top 5 most variable spliceosomal genes in common to MDAderived and CN-derived high variability subpopulations
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Figure 3.36: Variable cell-to-cell expression of SNRNP40 protein in high
variability subpopulations
Subpopulations were quantified for SNRNP40 protein levels by
fluorescence confocal microscopy (a) and analyzed for protein expression
coefficient of variation (b). P-values were derived from two-sample
(MDA) or one-sample (CN) one-sided t-test.

To determine whether population-level variation in SNRNP40
observed with high variability cells was sufficient to enforce metastatic
fitness, a low variability subpopulation was used to enforce modulation of
SNRNP40 expression. Populations of LV-M100 cells were individually
transduced with SNRNP40 over-expression constructs and shRNAs
targeting SNRNP40 at various titers to generate populations with varying
levels of SNRNP40 (Figure 3.37a). These populations were pooled to
generate a mixed population with increased cell-to-cell SNRNP40
expression variability without significantly altering mean SNRNP40
expression (Figure 3.37b; mean: Control = 9.0, hiCV=8.9, P = 0.19 by twosided t-test; CV: Control = 0.068, hiCV= 0.104, P = 7e-14 by Levene’s test).
Functional testing of this population in metastasis revealed that increased
140

cell-to-cell variability in SNRNP40 expression enhanced the ability of
these cells to metastasize more efficiently and colonize more sites
systemically (Figure 3.37), suggesting that variation in SNRNP40 between
cells could, in part, contribute to enhanced metastatic capacity observed in
high variability subpopulations. Next, SNRNP40 over-expression and
depletion cell lines were tested individually to determine whether the cells
with increased or decreased SNRNP40 expression imparted the enhanced
fitness to the pooled population. While increased SNRNP40 expression
did not affect metastatic capacity, SNRNP40 depletion promoted systemic
metastatic colonization (Figure 3.38).
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Figure 3.37: Engineered variation of SNRNP40 increases metastatic
colonization
(a) Populations of LV-M100 cells were generated with over-expression of
SNRNP40, shRNA-mediated knockdown of SNRNP40, empty vector, or
control shRNA vector at varying titers to generate various populationlevel expression of SNRNP40 as measured by qRT-PCR. (b) Populations
generated in (a) were pooled to generate a high SNRNP40 expression
variability LV-M100 population and were assayed for protein expression
by fluorescence microscopy. (c) 10

5

cells from pooled LV-M100

populations were inoculated via intracardiac injection and monitored by
bioluminescence flux. Representative mice are shown. P-value was
derived from one-sided t-test; n = 6. (d) Systemic metastatic foci per mice
were counted as distinct, minimal bioluminescence signals. P-value was
derived using one-sided t-test.
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Figure 3.38: SNRNP40 depletion, not over-expression, promotes
metastatic colonization
(a) 10 LV-M100 cells with SNRNP40 over-expression were inoculated by
5

intracardiac injection and monitored by bioluminescence; n=5. (b) 10 LV5

M100 cells with SNRNP40 depletion were inoculated by intracardiac
injection and monitored by bioluminescence. Representative mice are
shown; n=5. (c) Systemic metastatic foci per mice were counted. P-values
were derived from one-sided t-test.
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SNRNP40 regulates genes found to be variable in high variability subpopulations
and is required for proper intron exclusion
The next goal was to determine whether SNRNP40 contributed to
the gene expression variability seen in high variability subpopulations.
The working model was that variable levels of SNRNP40 allows for
transmission of variability to many transcripts dependent on SNRNP40
expression. Thus, siRNA-mediated depletion of SNRNP40 followed by
RNA-sequencing was performed to identify these dependent transcripts
with high magnitude of expression change indicative of strong
transmission. If variable expression of SNRNP40 contributes to gene
expression variability seen in high variability subpopulations, SNRNP40dependent transcripts would be enriched among variable transcripts in
high variability subpopulations. Indeed, transcripts with high magnitude
expression change in SNRNP40 knockdown cells were enriched among
variable transcripts between high variability single cells (Figure 3.39a).
Additionally, absolute log-fold expression change significantly correlated
with single-cell transcript variability ratios (Figure 3.39b). These findings
suggest that SNRNP40 contributes in part to the expression of a set of
variable transcripts in breast cancer cells. Additionally, SNRNP40
depletion led to an increase in intron retention (Figure 3.40), consistent
with

intron

retention

variability

observed

in

high

variability

subpopulations, although the modest effect may be attributed to
perturbation of only a single spliceosomal gene.
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Figure 3.39: SNRNP40 regulates gene expression consistent with gene
expression variability seen in highly variable subpopulations.
LV-M100 cells were transfected with two siRNAs targeting SNRNP40 and
processed for gene expression analysis. (a) Absolute log-fold change was
calculated to determine the magnitude of change. High magnitude change
was defined as absolute log-fold change > 1. Highly variable transcripts
were defined using single-cell RNA-sequencing experiments as log (HV2

M42/LV-M26 transcript CV ratio) > 1.5. The calculated mutual
information value (in bits) and z-score are provided. P-value was derived
using two-sided Fisher’s exact test. Also shown are the enrichment scores,
presented as logP (positive for enrichments and negative for depletions),
where P is calculated from hypergeometric distribution (shown as a
heatmap with blue and gold showing depletion and enrichment,
respectively). (b) Gene expression variability ratios of 6,906 transcripts
derived from single-cell RNA-sequencing were binned into 100 bins. For
transcripts in each bin, the absolute log-fold expression change of
SNRNP40 siRNA treatment relative to control siRNAs was calculated,
averaged, and plotted. Robust linear regression is shown in black. Twosided spearman’s correlation and corresponding p-value are shown.
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Figure 3.40: SNRNP40 promotes proper intron exclusion
Log-fold intron retention ratio was calculated for each transcript and
plotted as a histogram. Dashed red line indicates mean. Percentages of
intron retention ratios above and below zero are shown. P-value was
derived from two-sided t-test of log-ratio as compared to zero.

Low SNRNP40 is associated with metastasis in human breast cancer
Given the experimental role of SNRNP40 in metastasis, human
breast cancer samples were assessed for SNRNP40 expression to
determine if this gene was associated with clinical outcomes. Indeed,
decreased SNRNP40 transcript-level expression in bulk primary breast
cancer sampled was associated with increased metastatic relapse
outcomes in multiple independent datasets (Figure 3.41). Furthermore,
low SNRNP40 copy number correlated with worse overall survival
(Figure 3.41). These findings provide clinical association support for
SNRNP40 expression in human breast cancer progression. While tumors
can achieve reduced SNRNP40 expression through mean expression or
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copy number changes, our experimental model suggests that cancer
subpopulations may achieve SNRNP40 silencing through deregulation in
a subset of cells that is not easily observed using averaged measurements.

Figure 3.41: Low SNRNP40 expression is associated with metastasic
outcomes in human breast cancer
Kaplan-Meier curves of distant metastasis-free survival (DMFS) from
GSE33926 (Kuo et al., 2012) (a), GSE2034 (Wang et al., 2005) (b) and
kmplotter meta-analysis (Gyorffy et al., 2010) (c) as a function of primary
tumor SNRNP40 expression in breast cancer. (d) Kaplan-Meier curve of
overall survival from TCGA samples based on SNRNP40 copy number
(Cancer Genome Atlas, 2012). P-values were derived from log-rank test.
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3.7 Discussion
Cell-to-cell gene expression variability
Gene expression variability in cell populations can be driven by a
combination of stochastic and deterministic processes (Hanna et al., 2010).
While stochastic changes can impact population fitness, deterministic
processes can more reliably benefit evolution over multiple generations.
Single-cell transcriptomic analyses have revealed deterministic molecular
programs that regulate gene expression heterogeneity in induced
pluripotent stem cell differentiation and immune cells responses
(Buganim et al., 2012; Shalek et al., 2013). In cancer, analysis of gene
expression cell-to-cell variability has been limited though has mainly
pertained

to

stem-like

characteristics

of

individual

cells

within

glioblastoma tumors (Patel et al., 2014). The work presented here
illustrates another regulatory program involved in cell-to-cell gene
expression variability, namely variable splicesomal gene expression
between cells as a catalyst for gene expression variability.

Splicing as regulator of global gene expression networks
While constitutive splicing serves a necessary processing function
to generate protein-coding transcripts from genomic sequences, minimal
deregulation of splicing factors has the potential for amplified alterations
of gene regulatory networks and gene expression states. Key splicing
factors are understood to be required for maintenance of robust
transcriptomes as feedback loops exist to maintain steady-state levels and
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direct molecular programs (Jangi and Sharp, 2014). Furthermore, bonemarrow-derived

dendritic

cell

populations

in

response

to

lipopolysaccharide display variability in splice isoforms between cells
(Shalek et al., 2013). Consistent with the findings presented here,
heterogeneous transcriptional signatures and splice isoform variation
have been observed in glioblastoma (Patel et al., 2014) and likely
contribute to cancer progression. Additionally, intron retention has been
observed to regulate the expression of genes involved in nuclear shape as
well as splicing factor genes (Wong et al., 2013), indicating a complex
regulatory network as well as phenotypic consequences associated with
perturbed splicing.

Upstream source of molecular variability
While spliceosome gene expression variability has the potential to
contribute in part to the observed transcriptomic and phenotypic
variability in high variability subpopulations, the upstream cause of this
transcript-level

variability

remains

unknown.

One

approach

to

characterize the source is to determine whether the observed variability is
due to dynamic variability within a single cell, namely high fluctuations in
gene expression over time, or stable variation between cells, namely
certain cells always express low levels while other cells always express
high levels. Dynamic variability within cells would suggest that molecular
instability at the level of transcription or stability mediate transcript-level
variability, whereas stable variation between cells would suggest unequal
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cell divisions might be responsible. This question can be addressed by
using a fluorescent reporter of endogenous transcripts that display high
variability and performing live cell imaging to visualize protein
expression levels between cells and over time.
Given the maintained genomic integrity in these populations,
epigenetic alterations are a likely candidate for the source of variability.
Histone modifications and methylation of CpG islands are known to
contribute to cancer progression and have known roles in affecting
robustness of transcriptional activity (Rodriguez-Paredes and Esteller,
2011). Future experiments include analysis of transcriptional activity of
variable genes as well as analysis of DNA methylation in single cells
within highly variable subpopulations. Furthermore, if epigenetic
alterations are contributing to phenotypic and molecular variability, the
use of epigenetic drugs has the potential to suppress variability and slow
cancer evolution.
Additionally, the class of genes known as phenotypic capacitors
have the potential to contribute to transcript-level variability. Phenotypic
capacitors function to buffer noise and maintain phenotypic robustness;
thus, upon failure of a capacitor under external pressures, systems lose
robustness and result in greater phenotypic variability. The first capacitor
described was Hsp90, whose decreased expression resulted in uncovering
of genetically-encoded morphological variation as well as developmental
plasticity (Queitsch et al., 2002; Rutherford and Lindquist, 1998). To assess
whether capacitors could contribute to variability observed in breast
cancer populations, loss-of-function screens could be performed to
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identify capacitors that regulate phenotypes and molecular functions
identified in highly variable subpopulations. These screens have
previously been performed in yeast and have identified chromatin
remodeling complexes as capacitors (Levy and Siegal, 2008), supporting
the notion of epigenetic alterations as a potential contributor to cell-to-cell
variability.
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3.7 Materials and Methods
Cell culture
MDA-MB-231, CN34, and derived sub-population cells were propagated
as previously described (Tavazoie et al., 2008). MDA-MB-231 cells and
their derivatives were maintained in DMEM supplemented with 10% FBS,
glutamine, pyruvate, penicillin, streptomycin and Fungizone. CN34 cells
and their derivatives were maintained in M199 supplemented with 2.5%
FBS, 10 !g ml insulin, 0.5 !g ml hydrocortisone, 20 ng ml EGF, 100 ng
−1

−1

−1

ml cholera toxin, glutamine, pyruvate, penicillin, streptomycin and
−1

Fungizone. Cells in culture were routinely tested for mycoplasma
contamination. Clonal populations were generated by seeding cells
sparsely, picking individual colonies using cloning discs (Sigma), and
expanding the populations to approximately 10 cells when cells were
5

seeded to be imaged for size measurements.

Cell size measurements and coefficient of variation analysis
3x10 cells were seeded on coverslips and stained with HCS CellMask Red
4

(Invitrogen) and DAPI. Numerous fields were imaged on DeltaVision
Image Restoration Microscope to capture at least 100 cells per population.
Cell size parameters were measured using Cell Profiler 2.0. Debris was
filtered out by generating a histogram of (cytoplasmic area – nuclear area)
and applying a minimum threshold in R. To calculate coefficient of
variation (standard deviation / mean) for each clonal population, a
sampling size was determined from the clonal population with the fewest
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cells analyzed (96 cells in the MDA-MB-231 population and 206 cells in the
CN34 population). Subpopulations with more cells imaged than the
sampling size were sampled 100 times, with the average CV used in the
final analysis. For each subpopulation, coefficient of variation was
calculated for each size parameter, which includes cell area, cytoplasmic
area, nucleus, perimeter, major axis length, and minor axis length.
Principal component analysis was performed using all subpopulations on
the coefficient of variations for all morphological parameters. The first
principal component accounted for 93% and 91% of the variance in MDA
and CN34 cell lines, respectively, and is used for all size variation
analyses.

Three-dimensional size coefficient of variation analysis
Cells were fixed in 8% paraformaldehyde, permeabilized with 0.1%
Triton-X, and stained with HCS CellMask Red. Cells were analyzed by
ImageStream-X (Amnis) to measure cell size, nuclear size, perimeter,
major axis, and minor axis. Principal component analysis was performed,
and the first principal component was used for analyses.

Proliferation & colony formation assays
For bulk population proliferation assays, 5x10 cells were seeded in
3

triplicate and assayed WST-1 reagent (Roche) 72 hours after seeding. For
colony formation assays, 200 cells were seeded in 10cm plates in triplicate
and were allowed to grow for 10 days (MDA-derived cells) or 20 days
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(CN-derived cells). Plates were fixed in 6% glutaraldehyde with 0.5%
crystal violet and scanned. Colony areas were measured using ImageJ. R
was used to remove debris, equalize colony numbers with samplings as
above, and calculate coefficient of variation.

Animal studies
Animal experiments were conducted in accordance with protocols
approved by the Institutional Animal Care and Use Committee at The
Rockefeller University. For in vivo experiments with MDA-derived cell
lines, populations were transduced with a retroviral construct expressing
a luciferase reporter (Ponomarev et al., 2004). CN34 parental cell line was
previously labeled with luciferase reporter. Athymic female mice were
used for intracardiac injection. NOD-SCID female mice were used for tail
vein injections with MDA-derived cells, while NOD-SCID gamma female
mice were used for tail vein injections with CN-derived cells. For
intracardiac injections, cells in PBS were injected into the left ventricle of
mice in a volume of 100ul. For tail vein injections, cells in PBS were
injected into the tail vein of mice in a volume of 100ul. Portal circulation
injections were performed as described in chapter 2.8. For portal
circulation injection of mixed population, LV-M100 cells were transduced
with pLKO.1 puro (Addgene plasmid #8453), and HV-M42 cells were
transduced with pLKO.1 blast (Addgene plasmid #26655). Cells were
mixed at a 1:1 ratio immediately before injections. In vivo bioluminescence
was performed as described in chapter 2.8.
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Tissue microarray analysis
NCI CDP Breast Cancer Progression Tissue Microarray slides were
deparaffinized, rehydrated, and exposed to Heat Induced Epitope
Retrieval at pH 6 (Vector Labs) in a pressure cooker for 4 minutes. Slides
were stained with DAPI, and tumor cores were imaged on Leica TCS SP5
system at 40x. Images were analyzed using CellProfiler 2.0 to identify and
measure cancer cell nuclei by Otsu Adaptive thresholding. A minimum
nuclei size threshold was applied to remove stromal cell nuclei. Image
acquisition and analysis were blinded until measurements were
completed for all tumor cores. Mitotic index was calculated as follows: #
mitotic cells / total cells for each tumor core.

Exome sequencing and analysis
Genomic DNA was extracted using DNEasy kit (Qiagen). Libraries were
prepared using Nextera Extended Exome sequencing kit, as per
manufacturer’s instructions (Illumina), and paired-end sequenced on
HiSeq 2500 (Illumina). The analysis pipeline for the exome-seq data was
based on the GATK best practices. Reads were aligned to the human
genome (build hg19). The paired-end reads were then fixed and filtered
using Picard (v. 1.107; http://picard.sourceforge.net/). The duplicates
were also removed in the same step. Using GATK (v. 2.5) (McKenna et al.,
2010), the reads were realigned and recalibrated. mpileup (samtools (Li et
al., 2009)) was used to create an input for VarScan (v2.3.6) (Koboldt et al.,
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2012). In VarScan, mpileup2snp and mpileup2indel commands were used
to identify variants across all exome-seq samples. To study population
genetic divergence, the frequencies of all variants identified (148,234) were
used to generate phylogenic tree by Nei’s genetic distance using neighborjoining method in the PHYLIP package.
RNA-sequencing of bulk populations
For bulk population RNA-sequencing, RNA was extracted using total
RNA isolation kit (Norgen Biotek) with DNAse I treatment followed by
Ribo-Zero Gold rRNA removal (Epicentre). Libraries were generated
using ScriptSeq v2 RNA-seq Library Preparation Kit (Epicentre) and run
on HiSeq 2500 (Illumina). For RNA-sequencing data analysis, the reads
were trimmed to remove matches to linkers and low-quality bases
(cutadapt v1.2.1). Tophat (v. 2.0.8)(Kim et al., 2013) was then used to map
the reads to the human transcriptome (build hg19). Cufflinks and
cuffmerge (v.2.0.2) were then used to calculate reads per kilo base per
million (RPKM) and consolidated results across the samples. Finally,
cuffdiff (v.2.0.2) was used to calculate log-fold changes and the associated
statistics.

Single cell RNA-sequencing
Single cell isolation, cDNA synthesis, amplification, and processing for
Illumina sequencing were performed as described in detail (Islam et al.,
2012). To describe the protocol briefly, single cells were sorted by
fluorescence-activated cell sorting
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into 96-well plates containing cell lysis buffer, a biotin-labeled oligo-dT
primer for capturing poly-adenylated mRNA, and a template-switching
barcoded oligonucleotide to label transcripts from each cell. This
template-switching oligonucleotide is incorporated at the 5’ end of
complementary DNA generated in the next step. Once cells were
captured, Superscript II Reverse Transcriptase (Invitrogen) was used
under required buffer conditions to generate complementary DNA that
contained the biotin-labeled oligo-dT on the 3’ end and the barcoded
oligonucleotide on the 5’ end. Complementary DNA was captured and
purified using MyOne carboxylate Dynabeads (Life Technologies), then
PCR amplified using Advantage 2 DNA polymerase (Clontech) using a
biotinylated oligonucleotide. An aliquot of cDNA was checked for quality
by agarose gel electrophoresis. Complementary DNA was next captured
and

purified

using

MyOne

C1

streptavidin

Dynabeads

(Life

Technologies). The complementary DNA was then processed for Illuminabased sequencing by fragmentation, end repair, dA tailing, adapter
ligation, PCR amplification, purification with AMPure XP beads
(Beckman Coulter), and gel size selection for amplicons 200-400bp in size.
Samples were then sequencing on HighSeq 2500 (Illumina). Ambion
ArrayControl RNA spikes (Ambion) were used in each well to assess
sequencing quality and fidelity. For data analysis, reads were distributed
into separate samples based on their barcodes. Cells were excluded if
wells were empty or generated library was low quality as assessed by the
number of total reads, number of mapped reads, a high percentage of
unmapped reads and a high percentage of spike-in reads (Stegle et al.,
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2015). To equalize the number of cells analyzed from each population,
cells were randomly selected and removed from analysis. The RNAsequencing pipeline described above was then used to measure gene
expression across RNA-sequencing data from each cell. In parallel,
TopHat results were parsed to count the presence of every exon-exon
junction across all the samples. Transcripts present in both cell
populations, present in more than 25% of all cells and expressed above
threshold mean of all cells based on a Gaussian distribution were included
for analysis. Non-linear cell clustering by t-Distributed Stochastic
Neighbor Embedding was performed using ‘tsne’ package in R. To
measure intron retention, the number of reads mapping to each exon or
intron were counted across the transcriptome for all samples. As a
measure of intron retention (IR), for each intron, the number of reads
mapping to that intron relative to the two spanning exons (r_int_ex) was
calculated. For CV measurements, retained introns and exon-exon
junctions were included in analysis if present in more than 25% of all cells.

Pathway analysis
iPAGE

(Goodarzi

et

al.,

2009)

pathway

analysis

(http://iget.c2b2.columbia.edu) was used to identify gene sets with
higher transcript variability in both HV subpopulations. Transcript
coefficient of variation log-ratios (HV / LV) were used to categorize
transcripts into four bins: bin 1 = negative log-ratio in both MDA-derived
and CN-derived comparisons, bins 2&3 = positive log-ratio in either
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MDA-derived or CN-derived comparison, and bin 4= positive log-ratio in
both MDA-derived and CN-derived comparisons. GO and KEGG
annotations were analyzed using a maximum p-value of 0.05 and
maximum genes per category of 200. Gene sets were only considered
relevant if enrichment was highest in bin 4 and lowest in bin 1.

Flow cytometry
For antibody staining, cells were prepared using Cytofix/Cytoperm (BD).
Dead cells were excluded using Live/DEAD Aqua (Invitrogen). Primary
antibodies used were anti-XPNPEP3 (Abcam, 1:200), anti-UPF2 (LSBio,
1:4) anti-ALDOA (Abcam, 1:8), anti-PABP (Abcam; 1:200), anti-HNRNPA1
(Cell Signaling, 1:30), anti-CD110 (BD, 1:50), anti-HNRNPA0 (Cell
Signaling, 1:50), anti-ESR1 (Thermo, 1:20), anti-MCF2 (1:10, LSBio, 1:10),
and anti-CSF2RA (1:30, eBiosciences) conjugated to Alexa555 or Alexa647
Zenon secondary antibodies (Invitrogen). Data aquisition was performed
on LSRII (BD). Data analysis was performed on FloJo. CV calculations
were performed using greater than 25x10 cells, an equal number of cells
3

per sample within each experiment. Ratios were calculated using the
average value of all high variability populations (MDA: HV-M35, HVM42, HV-M56; CN: HV-C57) and low variability populations (MDA: LVM26, LV-M52, LV-M100; CN: LV-C65, LV-C92, LV-C100). Cell cycle
analysis was performed by employing flow cytometry on fixed cells
stained with DAPI and determining cell cycle phases in FloJo.
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SNRNP40 protein quantitation
Cells were seeded onto coverslips, fixed with 4% paraformaldehyde,
permeabilized with 0.1% Triton X-100, and stained with DAPI and antiSNRNP40 antibody (HPA026527, 1:100, Sigma) followed by fluorescentconjugated secondary antibodies. Imaging was performed on Leica TCS
SP5 system. SNRNP40 relative protein level was determined using Cell
Profiler 2.0 by measuring total nuclear SNRNP40 fluorescence intensity as
demarcated by DAPI signal.

SNRNP40 cell line generation
To generate high CV SNRNP40 population, cell populations were
transduced individually at various titers with either virus for shRNA
expression (shRNA#1 TRCN0000074608 and shRNA#2 TRCN0000074610,
Sigma) or virus for stable ORF expression (pBabe puro vector, Addgene
#1764). Expression in individual populations was confirmed by
quantitative RT-PCR. Populations were then pooled at equal ratios to
generate mixed populations. Control population was generated similarly
using a non-targeting shRNA (SHC016, Sigma) and an empty expression
vector.

Quantitative RT-PCR
RNA was extracted using total RNA isolation kit (Norgen Biotek). cDNA
was generated using Superscript III (Invitrogen). Fast SYBR Green Master
Mix (Life Technologies) was used to analyze samples on Applied
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Biosystems 7900HT. Expression was normalized to GAPDH. Primers
sequences are as follows: SNRNP40 Forward:
CAGTGGAGCAGTGATGGAAT; SNRNP40 Reverse:
CCCTCTCACCTGTTTCACTATC; GAPDH Forward:
AGCCACATCGCTCAGACAC; GAPDH Reverse:
GCCCAATACGACCAAATCC; blasticidin Forward:
CCTGGGATCAAAGCCATAGT; blasticidin Reverse:
TTAGCCCTCCCACACATAAC; puromycin Forward:
GTCACCGAGCTGCAAGAA; puromycin Reverse:
CCGATCTCGGCGAACAC

siRNA transfection
The following siRNAs were used (IDT): siSNRNP40 #1:
GGAAUAGACAAUGAUAUC; siSNRNP40 #2:
GGAUUUGACCGACUGAUA. BLOCK-iT Fluorescent Oligo (Life
Technologies) and NC1 (IDT) were used as controls.
10 cells were seeded and were transfected the next day with siRNAs via
5

Lipofectaime 2000 (Invitrogen). Cells were extracted 48 hours later for
validation of knock-down by quantitative RT-PCR or for RNAsequencing. For RNA-sequencing, two siRNAs were used for SNRNP40
and control, and independent siRNA replicates were averaged.
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Clinical samples
GSE2034 (Wang et al., 2005) and GSE33926 (Kuo et al., 2012) were used to
generate Kaplan-Meier curves. Patients were stratified by SNRNP40
expression relative to median. KMplotter was used to assess distant
metastasis-free survival with follow up threshold of 8 years (Gyorffy et al.,
2010). TCGA sample data was stratified by SNRNP40 copy number
relative to median and was used to assess overall survival.(Cancer
Genome Atlas, 2012)

162

CHAPTER 4: Final Summary
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The work presented in this thesis addresses two aspects of
metastatic colonization, the most significant clinical event in advanced
cancer progression. The first part of this thesis explored the cellular and
molecular functions of a kinase that promotes liver colonization by
colorectal cancer, which is a significant cause of cancer mortality. A
systematic, unbiased approach was utilized to identify genes that promote
liver colonization in a mouse model of metastasis. PKLR, which encodes
the liver and red blood cell isozymes of pyruvate kinase, was identified as
a promoter of colonization of the liver in an organ-specific manner.
Assessment of PKLR expression in patient samples revealed an
association of PKLR levels with metastatic disease, consistent with
functional testing results. Characterization of the cellular defect upon
PKLR depletion revealed the requirement of PKLR for cell survival in the
tumor core, a survival defect that can be recapitulated in vitro under
conditions of high cell density and hypoxia. While PKLR functions under
physiologic conditions to promote glycolysis in hepatocytes and red blood
cells, PKLR promotes survival by negatively regulating the glycolytic
enzymatic activity of the predominant pyruvate kinase expressed in
cancer, PKM2, and allows for the maintenance of the primary intracellular
antioxidant, glutathione (Illustration 4.2). Furthermore, inhibition of
glutathione synthesis by RNAi as well as small-molecule therapy led to a
suppression of metastatic colonization, indicating the potential for clinical
utility. Our findings reveal the use of multiple pyruvate kinase isozymes
by colon cancer for enhanced regulatory control of glycolysis and
antioxidant generation. Furthermore, the microenvironment conditions
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that render colon cancer cells susceptible to cell death highlight the
metabolically demanding conditions upon liver colonization and reveal
potential for therapeutic targeting of these pathways.

Illustration 4.2: Regulation of glycolytic metabolism for metastasis

The second half of this thesis focused on the study of non-genetic
diversity as a contributor to metastatic fitness. First, imaging analysis of
clonal subpopulations derived from human breast cancer cells lines was
performed to enable the identification of subpopulations that generate
phenotypic

variability.

Characterization

of

these

high

variability

subpopulations revealed that phenotypic variability was heritable in
progeny and was relevant in multiple phenotypes. Consistent with a
positive role of diversification in cancer progression, high variability
subpopulations displayed increased metastatic fitness. Variability did not
appear to be genetic in nature as subpopulation genomic integrity
appeared intact. However, single cell transcriptomic analyses reveal
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elevated cell-to-cell gene expression variability that was maintained
within clonal cancer subpopulations. Furthermore, spliceosome-associated
gene expression variability was identified as one potential mechanism by
which clonal cancer populations could increase mature transcript
expression variability of target genes. One example of a functional role for
spliceosome gene expression variability was explored where engineered
variable cell-to-cell expression of SNRNP40 enabled enhanced metastatic
fitness through existence of a subpopulation with low SNRNP40
expression (Illustration 4.3). Importantly, gene expression profiles upon
SNRNP40 deregulation was consistent with this gene’s contribution to
gene expression variability observed in high variability subpopulations.
The consistent molecular variability observed in high variability
subpopulations derived from independent human cancer cell populations
was measured under different experimental assays and at both the
molecular and phenotypic levels, suggesting that the variability is
molecularly conserved and deterministic in nature. These experimental
observations can be tested in clinical correlates to characterize non-genetic
contributions to tumor evolution in patients.

Illustration 4.1: Model of spliceosome expression variability mediating
gene expression changes and metastatic capacity.
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